WO2020001474A1 - 苯并咪唑衍生物及其作为idh1抑制剂的应用 - Google Patents

苯并咪唑衍生物及其作为idh1抑制剂的应用 Download PDF

Info

Publication number
WO2020001474A1
WO2020001474A1 PCT/CN2019/092997 CN2019092997W WO2020001474A1 WO 2020001474 A1 WO2020001474 A1 WO 2020001474A1 CN 2019092997 W CN2019092997 W CN 2019092997W WO 2020001474 A1 WO2020001474 A1 WO 2020001474A1
Authority
WO
WIPO (PCT)
Prior art keywords
mmol
solution
mixture
ethyl acetate
stirred
Prior art date
Application number
PCT/CN2019/092997
Other languages
English (en)
French (fr)
Inventor
王大海
钱文远
刘世岚
陈曙辉
Original Assignee
南京明德新药研发有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京明德新药研发有限公司 filed Critical 南京明德新药研发有限公司
Priority to CN201980039036.1A priority Critical patent/CN112533903B/zh
Priority to CA3104760A priority patent/CA3104760C/en
Priority to EP19827510.9A priority patent/EP3816158B1/en
Priority to AU2019296173A priority patent/AU2019296173B2/en
Priority to KR1020217001715A priority patent/KR102584855B1/ko
Priority to US17/254,890 priority patent/US11407717B2/en
Priority to JP2020573027A priority patent/JP7258059B2/ja
Priority to EA202190009A priority patent/EA202190009A1/ru
Publication of WO2020001474A1 publication Critical patent/WO2020001474A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Definitions

  • the present invention relates to a series of benzimidazole compounds and their use as inhibitors of IDH1 mutants, and in particular to compounds represented by formula (I), tautomers thereof, or pharmaceutically acceptable salts thereof.
  • Isocitrate dehydrogenase is an important enzyme in the citric acid cycle and catalyzes the oxidative decarboxylation of isocitrate to 2-oxoglutarate (ie, 2- ⁇ -ketoglutarate, ⁇ -KG).
  • IDH1 This gene encodes a protein that is a NADP (+)-dependent isocitrate dehydrogenase found in the cytoplasm and peroxisomes, which contains a PTS-1 peroxidase-targeting signal sequence. The presence of this enzyme in the oxidative body suggests a role in internal NADPH regeneration.
  • Non-mutations such as wild-type IDH catalyze the oxidative decarboxylation of isocitrate while reducing NAD + (NADP + ) to NADP (NADPH):
  • IDH1 / 2 mutations have been found in a variety of tumors, including gliomas, acute myeloid leukemia (AML), chondrosarcoma, intrahepatic cholangiomas, melanoma, prostate cancer, and angioimmunoblastic T-cell lymphoma Protein (IDH 1 / 2m).
  • AML acute myeloid leukemia
  • chondrosarcoma chondrosarcoma
  • intrahepatic cholangiomas melanoma
  • prostate cancer angioimmunoblastic T-cell lymphoma Protein
  • IDH 1 / 2m angioimmunoblastic T-cell lymphoma Protein
  • IDH muteins have a new protein function, namely, catalytic reduction of ⁇ -KG to produce the carcinogenic metabolite 2-hydroxyglutaric acid (2-HG).
  • the production of 2-HG is believed to contribute to the formation and development of cancer (Dang L, Nature, 2009 Dec 10; 462 (7274): 739-44).
  • Normal cells produce very low levels of 2-HG, but cells with IDH mutations produce high levels of 2-HG. High levels of 2-HG can also be found in tumors with IDH mutations.
  • the present invention provides a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof,
  • R 1 is selected from C 1-6 alkyl, C 3-6 cycloalkyl and phenyl, said C 1-6 alkyl, C 3-6 cycloalkyl and phenyl optionally being 1, 2 or 3 R a substituted;
  • R 2 and R 3 are each independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, COOH, C 1-6 alkyl, and C 1-6 alkoxy, the C 1-6 Alkyl and C 1-6 alkoxy are optionally substituted with 1, 2 or 3 R b ;
  • R 1 and R 2 are joined together to form a C 4-6 cycloalkenyl group optionally substituted with 1, 2 or 3 R c ;
  • L is selected from -CH 2 CH 2 -and -C 3-6 cycloalkyl-CH 2 CH 2- ;
  • n is selected from 1, 2 and 3;
  • R a , R b and R c are each independently selected from F, Cl, Br, I, OH, NH 2 , CN, COOH and Me.
  • the R 1 is selected from C 1-3 alkyl, cyclopropanyl, and phenyl, and the C 1-3 alkyl, cyclopropanyl, and phenyl is optionally 1, 2, or 3 R a is substituted, other variables are as defined in the present invention.
  • R 1 is selected from the group consisting of CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 CH 2 CH 3 , C (CH 3 ) 3 , CH (CH 3 ) 2 and Other variables are as defined in the present invention.
  • R 2 and R 3 are independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, COOH, C 1-3 alkyl, and C 1-3 alkoxy Group, the C 1-3 alkyl group and the C 1-3 alkoxy group are optionally substituted with 1, 2 or 3 R b , and other variables are as defined in the present invention.
  • R 2 and R 3 are independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, COOH, CH 3 and CH 3 O, and CH 3 and CH 3 O optionally substituted with 1, 2 or 3 R b, the other variables are as defined in the present invention.
  • R 2 and R 3 are independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, COOH, CH 3 , CH 2 F, CHF 2 , CF 3 and OCH 3 , other variables are as defined in the present invention.
  • the above-mentioned L is selected from -CH 2 CH 2 -and Other variables are as defined in the present invention.
  • the present invention also has some solutions from any combination of the above variables.
  • the aforementioned compound, an isomer thereof, or a pharmaceutically acceptable salt thereof is selected from the group consisting of
  • E is selected from -CH 2- , -CH 2 CH 2- , -C (CH 3 ) 2- , and C (CH 3 ) 2 CH 2- ;
  • L is selected from -CH 2 CH 2 -and
  • R 1 , R 2 and R 3 are as defined in the present invention.
  • the aforementioned compound, an isomer thereof, or a pharmaceutically acceptable salt thereof is selected from the group consisting of
  • the present invention also provides a compound represented by the following formula, an isomer thereof, or a pharmaceutically acceptable salt thereof, the compound is selected from
  • the above compound is selected from the group consisting of
  • the invention also provides the application of the above-mentioned compound, its isomer or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a disease related to IDH1.
  • pharmaceutically acceptable refers to those compounds, materials, compositions, and / or dosage forms that are within the scope of sound medical judgment and are suitable for use in contact with human and animal tissues Without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit / risk ratio.
  • pharmaceutically acceptable salt refers to a salt of a compound of the present invention, prepared from a compound having a specific substituent and a relatively non-toxic acid or base found in the present invention.
  • base addition salts can be obtained by contacting a sufficient amount of a base with a neutral form of such compounds in a pure solution or a suitable inert solvent.
  • Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic ammonia or magnesium salts or similar salts.
  • acid addition salts can be obtained by contacting a neutral form of such compounds with a sufficient amount of acid in a pure solution or a suitable inert solvent.
  • Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, Hydrogen sulfate, hydroiodic acid, phosphorous acid, etc .; and organic acid salts, such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, Similar acids such as fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, and methanesulfonic acid; also include salts of amino acids (such as arginine, etc.) , And salts of organic acids such as glucuronic acid. Certain specific compounds of the present invention contain basic and acidic functional groups
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound containing an acid group or a base by a conventional chemical method. Generally, such salts are prepared by reacting these compounds in the form of a free acid or base with a stoichiometric appropriate base or acid in water or an organic solvent or a mixture of the two.
  • the compounds of the invention may exist in specific geometric or stereoisomeric forms.
  • This invention contemplates all such compounds, including cis and trans isomers, (-)-and (+)-enantiomers, (R)-and (S) -enantiomers, diastereomers Isomers, (D) -isomers, (L) -isomers, and racemic and other mixtures thereof, such as enantiomers or diastereomerically enriched mixtures, all of which belong to Within the scope of the invention.
  • Additional asymmetric carbon atoms may be present in substituents such as alkyl. All these isomers and their mixtures are included in the scope of the present invention.
  • enantiomers or “optical isomers” refer to stereoisomers in mirror image relationship to each other.
  • cis-trans isomer or “geometric isomer” are caused by the inability to rotate freely of double bonds or single bonds of ring-forming carbon atoms.
  • diastereomer refers to a stereoisomer in which a molecule has two or more centers of chirality and is in a non-mirror relationship between molecules.
  • wedge solid line keys And wedge-shaped dotted keys Represents the absolute configuration of a solid center
  • using straight solid line keys And straight dotted keys Represents the relative configuration of the solid center
  • with wavy lines Represents a wedge solid line key Or wedge-shaped dotted key Or with wavy lines Represents a straight solid line key And straight dotted keys
  • the following formula (A) indicates that the compound exists as a single isomer of formula (A-1) or formula (A-2) or as two isomers of formula (A-1) and formula (A-2) Exists in the form of a mixture;
  • the following formula (B) indicates that the compound exists as a single isomer of the formula (B-1) or (B-2) or in the form of both (B-1) and (B-2) The isomers exist as a mixture.
  • the following formula (C) represents that the compound exists as a single isomer of the formula (C-1) or (C-2) or in the form of the two isomers of the formula (C-1) and the formula (C-2) It exists as a mixture.
  • tautomer or “tautomeric form” means that at room temperature, the isomers of different functional groups are in dynamic equilibrium and can be quickly converted to each other. If tautomers are possible (eg in solution), the chemical equilibrium of the tautomers can be reached.
  • proton tautomers also known as prototropic tautomers
  • proton migration such as keto-enol isomerization and imine-ene Amine isomerization.
  • Valence tautomers include the recombination of some bonding electrons for mutual conversion.
  • a specific example of the keto-enol tautomerization is the interconversion between two tautomers of pentane-2,4-dione and 4-hydroxypent-3-en-2-one.
  • the terms “enriched with one isomer”, “enriched with isomers”, “enriched with one enantiomer” or “enantiomerically enriched” refer to one of the isomers or the The enantiomeric content is less than 100%, and the content of the isomer or enantiomer is 60% or more, or 70% or more, or 80% or more, or 90% or more, or 95% or more, or 96% or more, or 97% or more, or 98% or more, or 99% or more, or 99.5% or more, or 99.6% or more, or 99.7% or more, or 99.8% or more, or more 99.9%.
  • the terms “isomer excess” or “enantiomeric excess” refer to the difference between the two isomers or the relative percentages of the two enantiomers. For example, if one of the isomers or enantiomers is 90% and the other isomer or enantiomer is 10%, the isomer or enantiomeric excess (ee value) is 80% .
  • Optically active (R)-and (S) -isomers and D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If an enantiomer of a compound of the invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, in which the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide a pure The desired enantiomer.
  • a diastereomeric salt is formed with an appropriate optically active acid or base, and then a conventional method known in the art Diastereomeric resolution is performed and the pure enantiomer is recovered.
  • the separation of enantiomers and diastereomers is usually accomplished by using chromatography that employs a chiral stationary phase and is optionally combined with chemical derivatization (for example, the formation of amino groups from amines) Formate).
  • the compounds of the present invention may contain atomic isotopes in unnatural proportions on one or more of the atoms constituting the compound.
  • compounds can be labeled with radioisotopes, such as tritium ( 3 H), iodine-125 ( 125 I), or C-14 ( 14 C).
  • deuterated drugs can be replaced by heavy hydrogen. The bond between deuterium and carbon is stronger than the bond between ordinary hydrogen and carbon. Compared with non-deuterated drugs, deuterated drugs have lower toxicity and increased drug stability. , Enhance the efficacy, extend the biological half-life of drugs and other advantages. Transformations of all isotopic compositions of the compounds of the invention, whether radioactive or not, are included within the scope of the invention.
  • substituted refers to the replacement of any one or more hydrogen atoms on a specific atom with a substituent, and may include deuterium and hydrogen variants, as long as the valence of the specific atom is normal and the substituted compound is stable of.
  • it means that two hydrogen atoms are substituted.
  • Oxygen substitution does not occur on aromatic groups.
  • optionally substituted means that it may or may not be substituted, and unless otherwise specified, the kind and number of substituents may be arbitrary on the basis of chemically achievable.
  • any variable (such as R) appears more than once in the composition or structure of a compound, its definition in each case is independent.
  • R when any variable (such as R) appears more than once in the composition or structure of a compound, its definition in each case is independent.
  • the group may optionally be substituted with at most two R, and R in each case has independent options.
  • combinations of substituents and / or variants are only permitted if such combinations result in stable compounds.
  • linking group When the number of a linking group is 0, such as-(CRR) 0- , it means that the linking group is a single bond.
  • substituents When a substituent is vacant, it means that the substituent does not exist. For example, when X is vacant in AX, it means that the structure is actually A.
  • substituents When the enumerated substituents do not indicate through which atom they are attached to the substituted group, such substituents may be bonded through any of its atoms, for example, pyridyl as a substituent may be passed through any of the pyridine rings The carbon atom is attached to a substituted group.
  • the listed linking group does not indicate its connection direction, its connection direction is arbitrary, for example, The intermediate linking group L is -MW-. At this time, -MW- can be connected to ring A and ring B in the same direction as the reading order from left to right. You can also connect ring A and ring B in the opposite direction from the reading order from left to right.
  • Combinations of the linking groups, substituents, and / or variants thereof are permitted only if such combinations result in stable compounds.
  • C 1-6 alkyl is used to indicate a straight or branched chain saturated hydrocarbon group consisting of 1 to 6 carbon atoms.
  • the C 1-6 alkyl includes C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C 6 and C 5 alkyl, etc .; it may Is monovalent (such as methyl), divalent (such as methylene) or polyvalent (such as methine).
  • C 1-6 alkyl examples include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl , S-butyl and t-butyl), pentyl (including n-pentyl, isopentyl and neopentyl), hexyl and the like.
  • C 1-3 alkyl is used to indicate a straight or branched chain saturated hydrocarbon group consisting of 1 to 3 carbon atoms.
  • the C 1-3 alkyl group includes C 1-2 and C 2-3 alkyl groups and the like; it may be monovalent (such as methyl), divalent (such as methylene), or polyvalent (such as methine).
  • Examples of C 1-3 alkyl include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), and the like.
  • C 1-6 alkoxy refers to those alkyl groups containing 1 to 6 carbon atoms that are attached to the rest of the molecule through one oxygen atom.
  • the C 1-6 alkoxy group includes C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C 6 , C 5 , C 4 and C 3 alkoxy, etc. .
  • C 1-6 alkoxy examples include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutyl Oxy, s-butoxy and t-butoxy), pentyloxy (including n-pentyloxy, isopentyloxy and neopentyloxy), hexyloxy, and the like.
  • C 1-3 alkoxy refers to those alkyl groups containing 1 to 3 carbon atoms that are attached to the rest of the molecule through one oxygen atom.
  • the C 1-3 alkoxy group includes C 1-2 , C 2-3 , C 3 and C 2 alkoxy, and the like.
  • Examples of C 1-3 alkoxy include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), and the like.
  • C 3-6 cycloalkyl means a saturated cyclic hydrocarbon group consisting of 3 to 6 carbon atoms, which is a monocyclic and bicyclic system.
  • the C 3-6 cycloalkyl includes C 3-5 , C 4-5 and C 5-6 cycloalkyl, etc .; it may be monovalent, divalent or polyvalent.
  • Examples of C 3-6 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
  • C 4-6 cycloalkenyl means a partially unsaturated cyclic hydrocarbon group consisting of 4 to 6 carbon atoms containing at least one carbon-carbon double bond, and includes monocyclic and bicyclic System, in which the bicyclic ring system includes a spiro ring, a parallel ring and a bridge ring, and any ring in this system is non-aromatic.
  • the C 4-6 cycloalkenyl includes C 4-5 or C 5-6 cycloalkenyl, and the like; it may be monovalent, divalent, or polyvalent.
  • C 4-6 cycloalkenyl examples include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, and the like.
  • C 6-12 aromatic ring and “C 6-12 aryl” in the present invention are used interchangeably, and the terms “C 6-12 aromatic ring” or “C 6-12 aryl” mean A cyclic hydrocarbon group having a conjugated ⁇ -electron system composed of 6 to 12 carbon atoms, which may be a monocyclic, fused bicyclic or fused tricyclic system, wherein each ring is aromatic. It may be monovalent, divalent, or polyvalent, and C 6-12 aryl groups include C 6-10 , C 6-9 , C 6-8 , C 12 , C 10 and C 6 aryl groups, and the like. Examples of C 6-12 aryl include, but are not limited to, phenyl, naphthyl (including 1-naphthyl and 2-naphthyl, etc.).
  • C n-n + m or C n -C n + m includes any specific case of n to n + m carbons, for example, C 1-12 includes C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , and C 12 , and also include any range from n to n + m, for example, C 1-12 includes C 1-3 , C 1-6 , C 1-9 , C 3-6 , C 3-9 , C 3-12 , C 6-9 , C 6-12 , and C 9-12, etc.
  • n yuan to n + m means that the number of atoms on the ring is n to n + m.
  • 3-12-membered rings include 3-, 4-, 5-, 6-, 7-, 8-, and 9-membered rings.
  • 10-membered ring, 11-membered ring, and 12-membered ring including any range from n to n + m, for example, 3-12-membered ring includes 3-6-membered ring, 3-9-membered ring, 5-6-membered ring Ring, 5-7 member ring, 6-7 member ring, 6-8 member ring, and 6-10 member ring, etc.
  • leaving group refers to a functional group or atom that can be replaced by another functional group or atom through a substitution reaction (eg, an affinity substitution reaction).
  • representative leaving groups include triflate; chlorine, bromine, and iodine; sulfonate groups such as mesylate, tosylate, p-bromobenzenesulfonate, and p-toluenesulfonic acid. Esters, etc .; acyloxy, such as acetoxy, trifluoroacetoxy and the like.
  • protecting group includes, but is not limited to, "amino protecting group", “hydroxy protecting group” or “mercapto protecting group”.
  • amino protecting group refers to a protecting group suitable for preventing side reactions at the amino nitrogen position.
  • Representative amino protecting groups include, but are not limited to: formyl; acyl, such as alkanoyl (such as acetyl, trichloroacetyl, or trifluoroacetyl); alkoxycarbonyl, such as tert-butoxycarbonyl (Boc) ; Arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); Arylmethyl, such as benzyl (Bn), trityl (Tr), 1,1-di -(4'-methoxyphenyl) methyl; silyl, such as trimethylsilyl (TMS) and tert-butyl
  • hydroxy-protecting group refers to a protecting group suitable for preventing side reactions of hydroxyl groups.
  • Representative hydroxy protecting groups include, but are not limited to: alkyl groups such as methyl, ethyl, and tert-butyl; acyl groups such as alkanoyl (such as acetyl); aryl methyl groups such as benzyl (Bn), p-formyl Oxybenzyl (PMB), 9-fluorenylmethyl (Fm), and diphenylmethyl (diphenylmethyl, DPM); silyl groups such as trimethylsilyl (TMS) and tert-butyl Dimethylsilyl (TBS) and more.
  • alkyl groups such as methyl, ethyl, and tert-butyl
  • acyl groups such as alkanoyl (such as acetyl)
  • aryl methyl groups such as benzyl (Bn), p-formyl Oxybenzyl
  • the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and those familiar to those skilled in the art. Equivalent alternatives, preferred embodiments include, but are not limited to, the embodiments of the present invention.
  • the solvent used in the present invention is commercially available.
  • the present invention uses the following abbreviations: aq stands for water; HATU stands for O- (7-azabenzotriazol-1-yl) -N, N, N ', N'-tetramethylurea hexafluorophosphate ; EDC stands for N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride; m-CPBA stands for 3-chloroperoxybenzoic acid; eq stands for equivalent, equivalent; CDI stands for Carbonyl diimidazole; DCM stands for dichloromethane; PE stands for petroleum ether; DIAD stands for diisopropyl azodicarboxylate; DMF stands for N, N-dimethylformamide; DMSO stands for dimethyl sulfoxide; EtOAc stands for ethyl acetate Esters; EtOH for ethanol; MeOH for methanol; CBz for
  • the compound of the present invention has a good inhibitory effect on mutant IDH1R132H and IDH1R132C at the enzymatic level, and has no inhibitory effect on wild-type IDH protein; at the cell level, the compound of the present invention has effect on U87MG glia with IDH1R132H mutation Tumor cells have a good 2-HG inhibitory effect; the compounds of the present invention have significant inhibitory effects and good selectivity for IDH1 mutants, and at the same time have a better distribution ratio in brain tumors and para-brain tissue, which can reduce the effect on normal brain Potential side effects of the tissue.
  • Example 1B Under a nitrogen atmosphere, nickel chloride (1.99 g, 15.32 mmol) was added to a solution of Example 1A (1 g, 3.06 mmol) in methanol (20 mL). Cool to 0 ° C and slowly add sodium borohydride (695.57 mg, 18.39 mmol). The mixed solution was stirred at 15 ° C for 1 hour. The reaction was quenched by adding 100 mL of saturated ammonium chloride solution and stirring for 15 minutes. It was extracted with ethyl acetate (80 mL ⁇ 3), and the combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give Example 1B. It was used directly in the next step without purification.
  • Example 1B (1.1 g, 3.69 mmol) in a solution of tetrahydrofuran (20 mL) was added 4- (trifluoromethoxy) benzene isothiocyanate (888.84 mg, 4.06 mmol,), and stirred at 40 ° C for half an hour, then added EDC ⁇ HCl (1.41 g, 7.37 mmol) was stirred at 70 ° C for 16 hours.
  • the reaction solution was diluted with 30 mL of water, and then extracted with ethyl acetate (30 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. Purification by column chromatography gave Example 1C.
  • Example 1C (1.35 g, 2.79 mmol) was added to a mixed solution of tetrahydrofuran (10 mL) and water (10 mL), lithium hydroxide (334.35 mg, 13.96 mmol) was added, and the mixture was stirred at 15 ° C for 16 hours.
  • the reaction solution was adjusted to pH with 1M hydrochloric acid To 6. It was extracted with ethyl acetate (30 mL ⁇ 3), and the combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product.
  • Example 1 The crude product was diluted with 5 ml of ethyl acetate, 20 ml of petroleum ether was added thereto, a white solid precipitated, filtered, and concentrated under reduced pressure, and then diluted with 10 ml of methyl tert-butyl ether, stirred for ten minutes, filtered, and the solid was concentrated under reduced pressure to obtain Example 1.
  • Example 2B Under a nitrogen blanket, to a solution of Example 2A (1 g, 3.06 mmol) in methanol (20 mL) was added nickel chloride (1.99 g, 15.32 mmol). After cooling to 0 ° C, sodium borohydride (695.57mg, 18.39mmol) was slowly added, and the mixed solution was stirred at 15 ° C for 1 hour. 100 mL of saturated ammonium chloride solution was added to stir the reaction for 15 minutes to quench the reaction, and the mixture was extracted with ethyl acetate (80 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain Example 2B. step.
  • Example 2C To a solution of Example 2B (950.00mg, 3.18mmol) in tetrahydrofuran (2mL) was added 4- (trifluoromethoxy) benzene isothiocyanate (767.64mg, 3.50mmol), and the mixture was stirred at 40 ° C for half an hour, then added EDCI (1.22 g, 6.37 mmol) was stirred at 70 ° C for 16 hours. The reaction solution was diluted with 30 mL of water and then extracted with ethyl acetate (30 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography to obtain Example 2C.
  • Example 2C To a mixed solution of Example 2C (1.33 g, 2.75 mmol) in tetrahydrofuran (10 mL) and water (10 mL) was added lithium hydroxide (329.42 mg, 13.75 mmol), and the mixture was stirred at 15 ° C for 16 hours.
  • the reaction solution was adjusted with 1M hydrochloric acid pH to 6, extracted with ethyl acetate (30 mL x 3), the combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a crude product.
  • Example 3A The combined organic layers were washed with 200 mL (100 mL ⁇ 2) of a saturated sodium chloride aqueous solution and dried over anhydrous sodium sulfate. , Filtered and concentrated under reduced pressure to obtain a residue, which was purified by column chromatography to obtain Example 3A.
  • Example 3A To a solution of Example 3A (1.01 g, 2.80 mmol) in methanol (10 mL) and tetrahydrofuran (6 mL) was added nickel chloride (3.33 g, 14.00 mmol), followed by the dropwise addition of sodium borohydride (1.38 g, 36.39 mmol). A solution of dimethylformamide (3 mL), the internal temperature was controlled to not exceed 10 ° C, and the reaction mixture was stirred at 10 ° C for 1 hour.
  • Example 3B The mixture was added with water (80 mL) and ethyl acetate (30 mL) and filtered through a pad of celite, the filter cake was washed with ethyl acetate (40 mL x 3), the filtrate was extracted with 150 mL of ethyl acetate, and the combined organic phases were saturated brine ( 100mL ⁇ 2) Washed, dried over anhydrous sodium sulfate and concentrated in vacuo to obtain Example 3B, which was directly used in the next step.
  • Example 3B To a solution of Example 3B (711 mg, 2.14 mmol) in tetrahydrofuran (8 mL) was added 1-isothiocyanato-4- (trifluoromethoxy) benzene (515.06 mg, 2.35 mmol, 381.52 ⁇ L), and the mixture was at 45 Stir at 1 ° C for 1 hour, then add EDCI (409.53mg, 2.14mmol) and stir the mixture at 70 ° C for 15 hours.
  • Example 3C To a solution of Example 3C (713 mg, 1.38 mmol) in tetrahydrofuran (4 mL) and water (2 mL) was added lithium hydroxide (288.84 mg, 6.88 mmol), and the mixture was stirred at 20 ° C for 16 hours.
  • the combined organic layers were washed with 200 mL (100 mL ⁇ 2) saturated saline solution, dried over anhydrous sodium sulfate, filtered, and Concentrated under reduced pressure to give a residue.
  • Example 3D The residue was purified by high performance liquid chromatography (TFA conditions) to obtain Example 3D.
  • Example 4A To a solution of Example 4A (1.01 g, 2.93 mmol) in methanol (6 mL) and tetrahydrofuran (6 mL) was added nickel chloride (3.49 g, 14.67 mmol), and then sodium borohydride (1.44 g, 38.13 mmol) was added dropwise to dissolve the solution. In a solution of dimethylformamide (3 mL), the internal temperature was controlled to not exceed 10 ° C, and the reaction mixture was stirred at 10 ° C for 1 hour.
  • Example 4B The mixture was poured into water (80 mL) and ethyl acetate (30 mL) and filtered through a pad of celite, the filter cake was washed with ethyl acetate (40 mL x 3), the mixture was extracted with 150 mL of ethyl acetate, and the combined organic phases were It was washed with saturated brine (100 mL ⁇ 2), dried over anhydrous sodium sulfate and concentrated in vacuo to obtain Example 4B, which was directly used in the next step.
  • Example 4B To a solution of Example 4B (411 mg, 1.30 mmol) in tetrahydrofuran (6 mL) was added 1-isothiocyano-4- (trifluoromethoxy) benzene (313.22 mg, 1.43 mmol), and the mixture was stirred at 45 ° C for 1 Hours, then EDCI (249.04 mg, 1.30 mmol) was added and the mixture was stirred at 70 ° C for 15 hours.
  • Example 4C was purified by column chromatography and used directly in the next step.
  • Example 4C To a solution of Example 4C (333 mg, 664.05 ⁇ mol) in tetrahydrofuran (4 mL) and water (2 mL) was added lithium hydroxide (139.33 mg, 3.32 mmol), and the mixture was stirred at 20 ° C. for 16 hours.
  • Example 4 The residue was purified by high performance liquid chromatography (TFA conditions) to obtain Example 4.
  • Example 5A Used for the next step.
  • Example 5A 400 mg, 1.18 mmol
  • nickel dichloride hexahydrate (1.12 g, 4.70 mmol)
  • sodium borohydride 88.92 mg, 2.35 mmol
  • dimethyl Formamide 1mL
  • the reaction mixture was diluted with water (20 mL) and then filtered.
  • the filtrate was extracted with ethyl acetate (20 mL x 4).
  • the combined organic layers were washed with brine (40 mL x 1), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give Example 5B was used in the next step without further purification.
  • Example 5B To a solution of Example 5B (350 mg, 1.12 mmol) in tetrahydrofuran (5 mL) was added 4- (trifluoromethoxy) phenylthioisocyanate (270.12 mg, 1.23 mmol), and the mixture was stirred at 25 ° C for 1 hour. Then, EDCI (429.54 mg, 2.24 mmol) was added to the mixture and reacted at 70 ° C for 2 hours.
  • 4- (trifluoromethoxy) phenylthioisocyanate 270.12 mg, 1.23 mmol
  • Example 5C which was used directly in the next step without further purification.
  • Example 5C To a solution in Example 5C (500 mg, 1.01 mmol) and water (5 mL) was added lithium hydroxide monohydrate (126.52 mg, 3.02 mmol), and the mixture was stirred at 20 ° C for 16 hours. The pH of the mixture was adjusted to 6-7 with HCl (1M aqueous solution), the mixture was extracted with ethyl acetate (10 mL ⁇ 4), the combined organic layers were washed with brine (20m ⁇ 1), dried over anhydrous sodium sulfate, and filtered And concentrated under reduced pressure to obtain a residue, which was purified by high performance liquid chromatography (TFA conditions) to obtain Example 5.
  • TFA conditions high performance liquid chromatography
  • Example 6A which was used directly in the next step without purification.
  • Example 6A To a solution of Example 6A (1.31 g, 3.72 mmol) in methanol (10 mL) was added nickel chloride (4.42 g, 18.59 mmol), followed by the dropwise addition of sodium borohydride (1.97 g, 52.05 mmol) in dimethylformamide A solution of amide (3mL), controlling the internal temperature not to exceed 10 ° C, the reaction mixture was stirred at 10 ° C for 16 hours, the mixture was poured into water (100mL), ethyl acetate (40mL) and filtered through a pad of celite, filtered The cake was washed with ethyl acetate (60 mL ⁇ 3), and the mixture was extracted with 150 mL of ethyl acetate. The combined organic phases were washed with saturated brine (100 mL ⁇ 2), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give Example 6B. Purified and used directly in the next step.
  • Example 6B To a solution of Example 6B (1.09 g, 2.99 mmol) in tetrahydrofuran (15 mL) was added isothiocyano-4- (trifluoromethoxy) benzene (720.97 mg, 3.29 mmol), and the mixture was stirred at 50 ° C for 1 hour. Then, EDCI (573.25 mg, 2.99 mmol) was added and the mixture was stirred at 70 ° C for 15 hours.
  • Example 6C To a solution of Example 6C (1.36 g, 2.64 mmol) in tetrahydrofuran (10 mL) and water (4 mL) was added lithium hydroxide (554.44 mg, 13.21 mmol), and the mixture was stirred at 25 ° C for 16 hours.
  • the combined organic layers were washed with 200 mL of saline solution (100 mL ⁇ 2), dried over Na 2 SO 4 , Filtered and concentrated under reduced pressure to give a residue.
  • the residue was dissolved in EA (10 mL) and stirred at 25 ° C for 30 min, then the mixture was filtered and washed with ethyl acetate (2 x 10 mL) to give
  • Example 7A The crude product was purified by column chromatography to give Example 7A as a yellow oil.
  • Example 7A Under a nitrogen blanket, to a solution of Example 7A (0.79 g, 2.19 mmol) in methanol (10 mL) was added nickel chloride (1.42 g, 10.95 mmol). Cool to 0 ° C and slowly add sodium borohydride (828.40 mg, 21.90 mmol). The mixed solution was stirred at 15 ° C for 0.5 hours. The reaction was quenched by adding 50 mL of saturated ammonium chloride solution and stirring for 15 minutes. It was extracted with ethyl acetate (50 mL ⁇ 3), and the combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a yellow oil, Example 7B, which was used in the next step without further purification.
  • Example 7C As a yellow solid.
  • 4- (trifluoromethoxy) benzene isothiocyanate (486.02 mg, 2.22 mmol, 360.01 ⁇ L) was added and stirred at 40 ° C for half
  • EDC ⁇ HCl (708.46 mg, 3.70 mmol) was added and stirred at 70 ° C for 5 hours.
  • the reaction solution was diluted with 30 mL of water, and then extracted with ethyl acetate (30 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. Purification by column chromatography gave Example 7C as a yellow solid.
  • Example 7C To a mixed solution of Example 7C (0.58 g, 1.12 mmol) in tetrahydrofuran (5 mL) and water (5 mL) was added lithium hydroxide (234.96 mg, 5.60 mmol), and the mixture was stirred at 20 ° C for 16 hours.
  • the reaction solution was adjusted with 1M hydrochloric acid pH to 6, then diluted with 30 mL of water, extracted with ethyl acetate (30 mL x 3), the combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product.
  • the crude product was purified by high performance liquid chromatography to obtain Example 7.
  • Example 8A (720 mg, 2.13 mmol) in MeOH (20 mL) and DMF (5 mL) was added in portions NiCl 2 .6H 2 O (2.02 g, 8.51 mmol) and NaBH 4 (563.54 mg, 14.90 mmol). The mixture was stirred at 0 ° C for 1 hour. The reaction mixture was quenched by the addition of water (50 mL) and then diluted with ethyl acetate (50 mL). The mixture was filtered and extracted with ethyl acetate (30 mL x 3). The combined organic layers were washed with brine (100 mL x 1), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a brown oil, Example 8B. The residue was used in the next step without further purification.
  • Example 8B To a solution of Example 8B (800 mg, 2.58 mmol) in THF (10 mL) was added 4- (trifluoromethoxy) benzene isothiocyanate (677.91 mg, 3.09 mmol, 502.16 ⁇ L). The mixture was stirred at 30 ° C for 1 h. Then EDCI (988.19 mg, 5.15 mmol) was added and the mixture was stirred at 70 ° C for 2 hours. The reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (20 mL ⁇ 3). The combined organic layers were washed with brine (30 mL x 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue.
  • Example 8C 450 mg, 908.19 umol
  • THF 2 mL
  • H 2 O 2 mL
  • LiOH.H 2 O 114.33 mg, 2.72 mmol
  • the mixture was stirred at 20 ° C for 16 hours.
  • the pH of the mixture was adjusted to 7 with an aqueous HCl solution (1M), and then extracted with ethyl acetate (10 mL ⁇ 3).
  • the combined organic layers were washed with brine (20 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to obtain Example 8 by purification by high performance liquid chromatography.
  • Example 9A Under a nitrogen blanket, to a solution of Example 9A (0.66 g, 1.70 mmol) in methanol (10 mL) was added nickel chloride (1.10 g, 8.50 mmol). Cool to 0 ° C and slowly add sodium borohydride (642.86 mg, 16.99 mmol). The mixed solution was stirred at 20 ° C for 0.5 hours. The reaction was quenched by adding 50 mL of saturated ammonium chloride solution and stirring for 15 minutes. It was extracted with ethyl acetate (50 mL ⁇ 3), and the combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a yellow oil, Example 9B, which was used in the next step without purification.
  • Example 9C As a yellow solid.
  • 4- (trifluoromethoxy) benzene isothiocyanate (278 mg, 1.27 mmol, 205.93 ⁇ L) was added and stirred at 40 ° C for 1 hour.
  • EDC ⁇ HCl (436.11 mg, 2.27 mmol) was added and stirred at 70 ° C for 12 hours.
  • the reaction solution was diluted with 30 mL of water, and then extracted with ethyl acetate (30 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. Purification by column chromatography gave Example 9C as a yellow solid.
  • Example 10A To a solution of Example 10A (1.19 g, 3.34 mmol) in methanol (10 mL) was added nickel chloride (3.97 g, 16.70 mmol), followed by the dropwise addition of sodium borohydride (1.39 g, 36.73 mmol) in dimethylformamide. An amide (5 mL) solution, the internal temperature was controlled to not exceed 10 ° C, and the reaction mixture was stirred at 10 ° C for 16 hours.
  • Example 10B The mixture was poured into water (100 mL), ethyl acetate (40 mL) and filtered through a pad of celite, the filter cake was washed with ethyl acetate (60 mL x 3) and the filtrate was extracted with 150 mL of ethyl acetate. The combined organic phases were used It was washed with saturated brine (100 mL ⁇ 2), dried over anhydrous sodium sulfate, and concentrated in vacuo to obtain Example 10B.
  • Example 10B To a solution of Example 10B (1.11 g, 3.35 mmol) in tetrahydrofuran (15 mL) was added 1-isothiocyanato-4- (trifluoromethoxy) benzene (734.27 mg, 3.35 mmol, 543.90 ⁇ L), and the mixture was Stir at 50 ° C for 1 hour, then add EDCI (642.11 mg, 3.35 mmol) and stir the mixture at 70 ° C for 15 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the residue was diluted with 100 mL of water and extracted with 200 mL (100 mL ⁇ 2) of ethyl acetate.
  • Example 10 Filtered and concentrated under reduced pressure, the resulting residue was dissolved in a mixed solution of ethyl acetate (4 mL) and petroleum ether (8 mL) and stirred at 25 ° C. for 60 minutes, and then the mixture was filtered and filtered with ethyl acetate (1 mL) and petroleum ether ( 2 mL) of the mixed solution was washed to obtain Example 10.
  • Example 11A 420 mg, 1.14 mmol
  • nickel chloride (1.35 g, 5.70 mmol)
  • sodium borohydride ((474.42 mg, 12.54 mmol) in dimethyl
  • formamide 3mL
  • the filter cake was washed with ethyl acetate (50 mL x 3), and the mixture was extracted with 100 mL of ethyl acetate.
  • the combined organic phases were washed with saturated brine (80 mL x 2), dried over anhydrous sodium sulfate and concentrated in vacuo to give Example 11B, Used directly in the next step without purification.
  • Example 11B To a solution of Example 11B (270 mg, 793.05 umol) in tetrahydrofuran (5 mL) was added 1-isothiocyanato-4- (trifluoromethoxy) benzene (173.82 mg, 793.05 ⁇ mol, 128.76 ⁇ L). Stir at 50 ° C for 1 hour, then add EDCI (167.23 mg, 872.35 ⁇ mol) and stir the mixture at 70 ° C for 15 hours.
  • EDCI 167.23 mg, 872.35 ⁇ mol
  • Example 12A To Example 12A (388 mg, 1.10 mmol) and nickel chloride hexahydrate (1.31 g, 5.51 mmol) were added MeOH (6 mL) and THF (6 mL), and sodium borohydride (416.54 mg, 11.01 mmol) was added in portions at 5 ° C. ) And stirred at 5 ° C for 0.5 hours. The reaction mixture was quenched by adding 100 mL of water, and then filtered. The filtrate was extracted with 100 mL (50 mL x 2) of ethyl acetate. The combined organic layers were washed with 50 mL of brine (50 mL x 1), dried over sodium sulfate, filtered, and concentrated under reduced pressure. Example 12B was obtained.
  • Example 12B To a solution of Example 12B (280 mg, 863.09 umol) in THF (15 mL), isothiocyanato-4- (trifluoromethoxy) benzene (227.01 mg, 1.04 mmol, 168.16 ⁇ L) was added. After the addition was completed, the mixture was stirred at 40 ° C. for 1 hour, then EDCI (330.91 mg, 1.73 mmol) was added, and stirred at 70 ° C. for 1 hour. The reaction mixture was concentrated under reduced pressure to remove THF, diluted with 80 mL of water and extracted with 100 mL of ethyl acetate (50 mL ⁇ 2).
  • Example 12C as a colorless oil.
  • Example 12C (0.29g, 569.16umol) was added with a solution of THF (3mL), MeOH (3mL) and H 2 O (3mL), lithium hydroxide monohydrate (119.41mg, 2.85mmol) was added, and the mixture was stirred at 20 ° C. 16 hours.
  • the combined organic layers were washed with 50 mL of brine, dried over sodium sulfate, filtered and concentrated under reduced pressure, and MeOH ( 10mL) beating, filtering, and drying under vacuum to obtain Example 12.
  • 3,3-Dimethylindan-1-one (3g, 18.73mmol) was dissolved in toluene (40mL), and titanium tetraisopropoxide (10.64g, 37.46mmol, 11.05mL) and 2-methylpropane- 2-sulfinamide (2.72g, 22.48mmol), stirred at 60 ° C for 24 hours, and then added 2-methylpropane-2-sulfinamide (2.72g, 22.48mmol) and titanium tetraisopropoxide (5.32g) , 18.73 mmol, 5.53 mL), and stirred at 110 ° C for 16 hours. The reaction mixture was quenched by adding 200 mL of water and then filtered.
  • Example 13A (1.4 g, 5.32 mmol) was dissolved in THF (20 mL) and water (574.67 mg, 31.89 mmol, 574.67 ⁇ L), and sodium borohydride (1.01 g, 26.58 mmol) was added, followed by stirring at 25 ° C. for 4 hours.
  • the reaction mixture was quenched by adding 100 mL of water, and then extracted with 100 mL (50 mL ⁇ 2) of ethyl acetate.
  • the combined organic layers were washed with 50 mL of a saturated common salt solution, dried over sodium sulfate, filtered, and concentrated under reduced pressure, and purified by column chromatography to obtain compound Example 13B as a white solid.
  • Example 13B (810mg, 3.05mmol) in MeOH (8mL) was added HCl / dioxane (4M, 3mL), stirred at 20 ° C for 0.5 hours, diluted with methyl tert-butyl ether (15mL) and diluted at 25 After stirring at 30 ° C for 30 minutes, filtering and drying under vacuum, Example 13C was obtained as a white solid.
  • Example 13D To a solution of methyl 3- (4-fluoro-3-nitro-phenyl) prop-2-enoate (400 mg, 1.78 mmol) in THF (12 mL) was added potassium carbonate (982.04 mg, 7.11 mmol). ) And Example 13C (491.69 mg, 2.49 mmol), stirred at 65 ° C for 16 hours, diluted with 100 mL of water and extracted with 120 mL of ethyl acetate (60 mL x 2), and the combined organic layers were washed with 50 mL of brine (50 mL x 1), Dry over sodium sulfate, filter, and concentrate under reduced pressure, and purify by column chromatography to give Example 13D as a yellow oil.
  • Example 13D (300 mg, 818.75 ⁇ mol) was dissolved in a solution of THF (5 mL) and MeOH (5 mL), Pd / C (50 mg, 10%) was added, and the solution was replaced with hydrogen 3 times at 25 ° C in H 2 (15 psi). Stir for 16 hours. Filtration and concentration of the filtrate under reduced pressure gave a brown oil, Example 13E.
  • Example 13E (255mg, 753.45umol) was dissolved in THF (8mL), and 1-isothiocyanato-4- (trifluoromethoxy) benzene (198.17mg, 904.14 ⁇ mol, 146.79 ⁇ L) was added and stirred at 40 ° C. After 1 hour, EDCI (288.87 mg, 1.51 mmol) was added and stirred at 70 ° C for 1 hour. The reaction mixture was concentrated under reduced pressure to remove THF, diluted with 80 mL of water and extracted with 100 mL of ethyl acetate (50 mL ⁇ 2).
  • a dry bottle was charged with 1- (trifluoromethyl) -1,2-benzoiodo-3-one (3.28 g, 10.37 mmol) and CuBr (123.96 mg, 864.15umol, 26.32 ⁇ L).
  • the bottle was evacuated and backfilled three times with nitrogen.
  • azido (trimethyl) silane (2.49 g, 21.60 mmol, 2.84 mL) and styrene (900 mg, 8.64 mmol) dissolved in ACN (40 mL) were added to the above bottle.
  • the reaction mixture was stirred at 40 ° C for 1.5 hours.
  • the reaction mixture was diluted with water (40 mL) and extracted with DCM (20 mL x 3).
  • Example 14A To a solution of Example 14A (1.1 g, 5.11 mmol) in MeOH (15 mL) was added CuSO 4 (81.59 mg, 511.21 umol, 78.46 ⁇ L) and NaBH 4 (290.11 mg, 7.67 mmol). The mixture was stirred at 0 ° C for 1 h, and then at 20 ° C for 16 h. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL ⁇ 3). The combined organic layers were washed with brine (20 mL x 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a brown oil, Example 14B, which was used in the next step without further purification.
  • Example 14C To a solution of Example 14C (1 g, 2.54 mmol) in MeOH (20 mL) was added NiCl 2 ⁇ 6H 2 O (2.41 g, 10.14 mmol). NaBH 4 (959.38 mg, 25.36 mmol) was then added in portions at 0 ° C, and the mixture was held at 0 ° C for 1 hour. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (50 mL x 1), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give a brown oil. The residue Example 14D was used in the next step without further purification.
  • Example 14D To Example 14D (770 mg, 2.10 mmol) in THF (20 mL) was added 1-isothiocyanato-4- (trifluoromethoxy) benzene (552.78 mg, 2.52 mmol, 409.47 ⁇ L). The mixture was stirred at 40 ° C for 1 h. EDCI (805.79 mg, 4.20 mmol) was then added and the mixture was stirred at 70 ° C for 2 hours. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (30 mL ⁇ 3). The combined organic layers were washed (50mL) with brine, dried over Na 2 SO 4, filtered, and concentrated under reduced pressure to give a residue.
  • Example 14E To a solution of Example 14E (220 mg, 398.93 ⁇ mol) in MeOH (3 mL) and H 2 O (3 mL) was added LiOH.H 2 O (50.22 mg, 1.20 mmol). The mixture was stirred at 30 ° C for 16 h. The mixture was stirred at 30 ° C for another 3 hours. The pH of the mixture was adjusted to 5-6 with HCl (1M) solution, a solid was precipitated, filtered and dried to give Example 14.
  • Example 14F To a solution of Example 14F (300 mg, 543.99 ⁇ mol) in MeOH (4 mL) and H 2 O (4 mL) was added LiOH.H 2 O (68.48 mg, 1.63 mmol). The mixture was stirred at 30 ° C for 16 hours. The pH of the mixture was adjusted to 5-6 with HCl (1M) solution, a solid was precipitated, filtered and dried to give Example 15.
  • the IDH1 mutant catalyzes the reduction of NADPH-dependent ⁇ -KG ( ⁇ -ketoglutarate) to 2-HG (2-hydroxyglutaric acid), and the consumed NADPH can be read by fluorescence.
  • Basic reaction buffer 50mM KH 2 PO 4 , pH 7.5, 10mM MgCl 2 , 10% glycerol, 150mM NaCl, 0.05% BSA (bovine serum albumin), 2mM b-ME (2-mercaptoethanol), 0.003% Brij35 ( (Oxyethylene lauryl ether)
  • IDH1wt wild type: 65 ⁇ M isocitrate + 50 ⁇ M NADP
  • IDH1 (R132H): 1500 ⁇ M ⁇ -KG + 15 ⁇ M NADPH
  • IDH1 (R132C): 500 ⁇ M ⁇ -KG + 15 ⁇ M NADPH
  • the enzymatic level of the patent compound of the present invention has a good inhibitory effect on the mutant IDH1R132H and IDH1R132C, and has no inhibitory effect on the wild-type IDH protein.
  • IDH1 will catalyze the reduction of isocitrate to ⁇ -ketoglutarate ( ⁇ -KG) in vivo, while IDH1 mutant will further catalyze the reduction of ⁇ -KG to 2-hydroxyglutaric acid (2HG).
  • U87MG-IDH1-R132H cell line is a stable transfected cell line capable of stably expressing IDH1-R132H mutant, which is obtained by transfecting U87MG cells with IDH1-R132H.
  • HT1080 cell line contains endogenous IDH1-R132C mutant.
  • the IDH1 mutant cell line was seeded into a cell culture plate containing the compound at a density of 40,000 cells / well. The cells were incubated with the compounds for 3 days in a 37 ° C, 5% CO 2 incubator.
  • Inhibition rate% (CPD-ZPE) / (HPE-ZPE) ⁇ 100%
  • the cell viability data was used to calculate the cytotoxicity percentage (% cytotoxicity) of the compound on the IDH1 mutant cell line, and the calculation formula was:
  • Cytotoxicity% (1-CPD / ZPE) ⁇ 100%
  • HPE Mean signal of positive control well
  • the patent compound of the present invention has a good 2-HG inhibitory effect on U87MG glioma cells with IDH1R132H mutation.
  • HPbCD hydroxypropyl betacyclodextrin
  • Animals in group 1 were administered a single dose of the drug at a concentration of 1 mg / kg and a concentration of 0.5 mg / mL through a single tail vein injection, and animals in group 2 were administered a compound at a dose of 20 mg / kg and a concentration of 2 mg / mL by intragastric administration. Animals were cross-collected at 0.0833 (tail vein injection group only), 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hours after dosing. The LC-MS / MS method was used to determine the drug concentration in the plasma sample, and the kinetic parameters of the tested drug were shown in Table 4:
  • Example 6 of the present invention has good pharmacokinetic properties in mice.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

涉及苯并咪唑类化合物及其作为IDH1突变体抑制剂的应用，具体涉及式(Ι)所示化合物、其互变异构体或其药学上可接受的盐。

Description

苯并咪唑衍生物及其作为IDH1抑制剂的应用
相关申请的引用
本申请主张如下优先权：
CN201810672394.3，申请日2018-06-26。
技术领域
本发明涉及一系列苯并咪唑类化合物及其作为IDH1突变体抑制剂的应用，具体涉及式(Ι)所示化合物、其互变异构体或其药学上可接受的盐。
背景技术
异柠檬酸脱氢酶(Isocitrate dehydrogenase)是柠檬酸循环过程中的重要酶，催化异柠檬酸氧化脱羧成2-氧代戊二酸(即2-α-酮戊二酸，α-KG)。IDH 1这种基因编码的蛋白是在细胞质和过氧化物酶体中发现的NADP(+)-依赖性异柠檬酸脱氢酶，其中含有PTS-1过氧化物酶靶向信号序列。该酶在氧化物酶体中的存在暗示在用于内部NADPH再生中的作用。
非突变例如野生型IDH催化异柠檬酸氧化脱羧的同时，还原NAD +(NADP +)至NADP(NADPH):
异柠檬酸酯+NAD +(NADP +)→α-KG+CO 2+NADP(NADPH)+H +
已经在多种肿瘤，包括胶质瘤、急性髓性白血病(AML)、软骨肉瘤、肝内胆管瘤、黑色素瘤、***癌、血管免疫母细胞性T细胞淋巴瘤中，发现IDH 1/2突变蛋白(IDH 1/2m)。胶质瘤中，非原发性胶质母细胞瘤中70％以上具有IDH1突变，IDH1突变肿瘤中92.7％是精氨酸被组氨酸替代(即IDH1 R132H)(Hartmann C,Acta Neuropathol.2009Oct；1 18(4):469-74).
IDH突变蛋白具有新的蛋白功能，即催化还原α-KG生成致癌代谢物2-羟基戊二酸(2-HG)。2-HG的产生据信有助于癌症的形成和发展(Dang L,Nature,2009 Dec 10；462(7274):739-44)。正常细胞中产生2-HG的水平非常低，但是具有IDH突变的细胞能产生高水平的2-HG。在具有IDH突变的肿瘤中同样能够发现高水平的2-HG。
因此突变IDH及其新活性的抑制是用于癌症治疗的潜在方法，也就存在需要获得IDH突变体的抑制剂来抑制其产生2-HG的新作用。
Acta Neuropathol(2017,Vol(133),Issue 4,629–644)公开了化合物BAY1436032的具体结构。
Figure PCTCN2019092997-appb-000001
发明内容
本发明提供了式(Ⅰ)所示化合物、其异构体或其药学上可接受的盐，
Figure PCTCN2019092997-appb-000002
其中，
R 1选自C 1-6烷基、C 3-6环烷基和苯基，所述C 1-6烷基、C 3-6环烷基和苯基任选被1、2或3个R a取代；
R 2和R 3分别独立地选自H、F、Cl、Br、I、OH、NH 2、CN、COOH、C 1-6烷基和C 1-6烷氧基，所述C 1-6烷基和C 1-6烷氧基任选被1、2或3个R b取代；
或者，R 1和R 2连接在一起，形成一个任选被1、2或3个R c取代的C 4-6环烯基；
L选自-CH 2CH 2-和-C 3-6环烷基-CH 2CH 2--；
n选自1、2和3；
R a、R b和R c分别独立地选自F、Cl、Br、I、OH、NH 2、CN、COOH和Me。
本发明的一些方案中，上述R 1选自C 1-3烷基、环丙烷基和苯基，所述C 1-3烷基、环丙烷基和苯基任选被1、2或3个R a取代，其他变量如本发明所定义。
本发明的一些方案中，上述R 1选自CH 3、CH 2F、CHF 2、CF 3、CH 2CH 3、CH 2CF 3、CH 2CH 2CH 3、C(CH 3) 3、
Figure PCTCN2019092997-appb-000003
CH(CH 3) 2和
Figure PCTCN2019092997-appb-000004
其他变量如本发明所定义。
本发明的一些方案中，上述R 2和R 3分别独立地选自H、F、Cl、Br、I、OH、NH 2、CN、COOH、C 1-3烷基和C 1-3烷氧基，所述C 1-3烷基和C 1-3烷氧基任选被1、2或3个R b取代，其他变量如本发明所定义。
本发明的一些方案中，上述R 2和R 3分别独立地选自H、F、Cl、Br、I、OH、NH 2、CN、COOH、CH 3和CH 3O，所述CH 3和CH 3O任选被1、2或3个R b取代，其他变量如本发明所定义。
本发明的一些方案中，上述R 2和R 3分别独立地选自H、F、Cl、Br、I、OH、NH 2、CN、COOH、CH 3、CH 2F、CHF 2、CF 3和OCH 3，其他变量如本发明所定义。
本发明的一些方案中，上述L选自-CH 2CH 2-和
Figure PCTCN2019092997-appb-000005
其他变量如本发明所定义。
本发明的一些方案中，上述结构单元
Figure PCTCN2019092997-appb-000006
选自
Figure PCTCN2019092997-appb-000007
其他变量如本发明所定义。
本发明的一些方案中，上述结构单元
Figure PCTCN2019092997-appb-000008
选自
Figure PCTCN2019092997-appb-000009
Figure PCTCN2019092997-appb-000010
其他变量如本发明所定义。
本发明的一些方案中，上述结构单元
Figure PCTCN2019092997-appb-000011
选自
Figure PCTCN2019092997-appb-000012
Figure PCTCN2019092997-appb-000013
其他变量如本发明所定义。
本发明的一些方案中，上述结构单元
Figure PCTCN2019092997-appb-000014
选自
Figure PCTCN2019092997-appb-000015
Figure PCTCN2019092997-appb-000016
Figure PCTCN2019092997-appb-000017
其他变量如本发明所定义。
本发明还有一些方案由上述变量任意组合而来。
本发明的一些方案中，上述化合物、其异构体或其药学上可接受的盐，其选自
Figure PCTCN2019092997-appb-000018
其中，
E选自-CH 2-、-CH 2CH 2-、-C(CH 3) 2-和C(CH 3) 2CH 2-；
L选自-CH 2CH 2-和
Figure PCTCN2019092997-appb-000019
R 1、R 2和R 3如本发明所定义。
本发明的一些方案中，上述化合物、其异构体或其药学上可接受的盐，其选自
Figure PCTCN2019092997-appb-000020
Figure PCTCN2019092997-appb-000021
其中，
E、L、R 1、R 2和R 3如本发明所定义。
本发明还提供了下式所示化合物、其异构体或其药学上可接受的盐，所述化合物选自
Figure PCTCN2019092997-appb-000022
Figure PCTCN2019092997-appb-000023
本发明的一些方案中，上述化合物，其选自
Figure PCTCN2019092997-appb-000024
Figure PCTCN2019092997-appb-000025
Figure PCTCN2019092997-appb-000026
本发明还提供了上述的化合物、其异构体或其药学上可接受的盐在制备治疗与IDH1相关疾病的药物中的应用。
定义和说明
除非另有说明，本文所用的下列术语和短语旨在具有下列含义。一个特定的术语或短语在没有特别定义的情况下不应该被认为是不确定的或不清楚的，而应该按照普通的含义去理解。当本文中出现商品名时，意在指代其对应的商品或其活性成分。
这里所采用的术语“药学上可接受的”，是针对那些化合物、材料、组合物和/或剂型而言，它们在可靠的医学判断的范围之内，适用于与人类和动物的组织接触使用，而没有过多的毒性、刺激性、过敏性反应 或其它问题或并发症，与合理的利益/风险比相称。
术语“药学上可接受的盐”是指本发明化合物的盐，由本发明发现的具有特定取代基的化合物与相对无毒的酸或碱制备。当本发明的化合物中含有相对酸性的功能团时，可以通过在纯的溶液或合适的惰性溶剂中用足够量的碱与这类化合物的中性形式接触的方式获得碱加成盐。药学上可接受的碱加成盐包括钠、钾、钙、铵、有机氨或镁盐或类似的盐。当本发明的化合物中含有相对碱性的官能团时，可以通过在纯的溶液或合适的惰性溶剂中用足够量的酸与这类化合物的中性形式接触的方式获得酸加成盐。药学上可接受的酸加成盐的实例包括无机酸盐，所述无机酸包括例如盐酸、氢溴酸、硝酸、碳酸，碳酸氢根，磷酸、磷酸一氢根、磷酸二氢根、硫酸、硫酸氢根、氢碘酸、亚磷酸等；以及有机酸盐，所述有机酸包括如乙酸、丙酸、异丁酸、马来酸、丙二酸、苯甲酸、琥珀酸、辛二酸、反丁烯二酸、乳酸、扁桃酸、邻苯二甲酸、苯磺酸、对甲苯磺酸、柠檬酸、酒石酸和甲磺酸等类似的酸；还包括氨基酸(如精氨酸等)的盐，以及如葡糖醛酸等有机酸的盐。本发明的某些特定的化合物含有碱性和酸性的官能团，从而可以被转换成任一碱或酸加成盐。
本发明的药学上可接受的盐可由含有酸根或碱基的母体化合物通过常规化学方法合成。一般情况下，这样的盐的制备方法是：在水或有机溶剂或两者的混合物中，经由游离酸或碱形式的这些化合物与化学计量的适当的碱或酸反应来制备。
本发明的化合物可以存在特定的几何或立体异构体形式。本发明设想所有的这类化合物，包括顺式和反式异构体、(-)-和(+)-对对映体、(R)-和(S)-对映体、非对映异构体、(D)-异构体、(L)-异构体，及其外消旋混合物和其他混合物，例如对映异构体或非对映体富集的混合物，所有这些混合物都属于本发明的范围之内。烷基等取代基中可存在另外的不对称碳原子。所有这些异构体以及它们的混合物，均包括在本发明的范围之内。
除非另有说明，术语“对映异构体”或者“旋光异构体”是指互为镜像关系的立体异构体。
除非另有说明，术语“顺反异构体”或者“几何异构体”系由因双键或者成环碳原子单键不能自由旋转而引起。
除非另有说明，术语“非对映异构体”是指分子具有两个或多个手性中心，并且分子间为非镜像的关系的立体异构体。
除非另有说明，“(D)”或者“(+)”表示右旋，“(L)”或者“(-)”表示左旋，“(DL)”或者“(±)”表示外消旋。
除非另有说明，用楔形实线键
Figure PCTCN2019092997-appb-000027
和楔形虚线键
Figure PCTCN2019092997-appb-000028
表示一个立体中心的绝对构型，用直形实线键
Figure PCTCN2019092997-appb-000029
和直形虚线键
Figure PCTCN2019092997-appb-000030
表示立体中心的相对构型，用波浪线
Figure PCTCN2019092997-appb-000031
表示楔形实线键
Figure PCTCN2019092997-appb-000032
或楔形虚线键
Figure PCTCN2019092997-appb-000033
或用波浪线
Figure PCTCN2019092997-appb-000034
表示直形实线键
Figure PCTCN2019092997-appb-000035
和直形虚线键
Figure PCTCN2019092997-appb-000036
除非另有说明，当化合物中存在双键结构，如碳碳双键、碳氮双键和氮氮双键，且双键上的各个原子 均连接有两个不同的取代基时(包含氮原子的双键中，氮原子上的一对孤对电子视为其连接的一个取代基)，如果该化合物中双键上的原子与其取代基之间用波浪线
Figure PCTCN2019092997-appb-000037
连接，则表示该化合物的(Z)型异构体、(E)型异构体或两种异构体的混合物。例如下式(A)表示该化合物以式(A-1)或式(A-2)的单一异构体形式存在或以式(A-1)和式(A-2)两种异构体的混合物形式存在；下式(B)表示该化合物以式(B-1)或式(B-2)的单一异构体形式存在或以式(B-1)和式(B-2)两种异构体的混合物形式存在。下式(C)表示该化合物以式(C-1)或式(C-2)的单一异构体形式存在或以式(C-1)和式(C-2)两种异构体的混合物形式存在。
Figure PCTCN2019092997-appb-000038
本发明的化合物可以存在特定的。除非另有说明，术语“互变异构体”或“互变异构体形式”是指在室温下，不同官能团异构体处于动态平衡，并能很快的相互转化。若互变异构体是可能的(如在溶液中)，则可以达到互变异构体的化学平衡。例如，质子互变异构体(proton tautomer)(也称质子转移互变异构体(prototropic tautomer))包括通过质子迁移来进行的互相转化，如酮-烯醇异构化和亚胺-烯胺异构化。价键异构体(valence tautomer)包括一些成键电子的重组来进行的相互转化。其中酮-烯醇互变异构化的具体实例是戊烷-2,4-二酮与4-羟基戊-3-烯-2-酮两个互变异构体之间的互变。
除非另有说明，术语“富含一种异构体”、“异构体富集”、“富含一种对映体”或者“对映体富集”指其中一种异构体或对映体的含量小于100％，并且，该异构体或对映体的含量大于等于60％，或者大于等于70％，或者大于等于80％，或者大于等于90％，或者大于等于95％，或者大于等于96％，或者大于等于97％，或者大于等于98％，或者大于等于99％，或者大于等于99.5％，或者大于等于99.6％，或者大于等于99.7％，或者大于等于99.8％，或者大于等于99.9％。
除非另有说明，术语“异构体过量”或“对映体过量”指两种异构体或两种对映体相对百分数之间的差值。例如，其中一种异构体或对映体的含量为90％，另一种异构体或对映体的含量为10％，则异构体或对映体过量(ee值)为80％。
可以通过的手性合成或手性试剂或者其他常规技术制备光学活性的(R)-和(S)-异构体以及D和L异构体。如果想得到本发明某化合物的一种对映体，可以通过不对称合成或者具有手性助剂的衍生作用来制备，其 中将所得非对映体混合物分离，并且辅助基团裂开以提供纯的所需对映异构体。或者，当分子中含有碱性官能团(如氨基)或酸性官能团(如羧基)时，与适当的光学活性的酸或碱形成非对映异构体的盐，然后通过本领域所公知的常规方法进行非对映异构体拆分，然后回收得到纯的对映体。此外，对映异构体和非对映异构体的分离通常是通过使用色谱法完成的，所述色谱法采用手性固定相，并任选地与化学衍生法相结合(例如由胺生成氨基甲酸盐)。本发明的化合物可以在一个或多个构成该化合物的原子上包含非天然比例的原子同位素。例如，可用放射性同位素标记化合物，比如氚( 3H)，碘-125( 125I)或C-14( 14C)。又例如，可用重氢取代氢形成氘代药物，氘与碳构成的键比普通氢与碳构成的键更坚固，相比于未氘化药物，氘代药物有降低毒副作用、增加药物稳定性、增强疗效、延长药物生物半衰期等优势。本发明的化合物的所有同位素组成的变换，无论放射性与否，都包括在本发明的范围之内。
“任选”或“任选地”指的是随后描述的事件或状况可能但不是必需出现的，并且该描述包括其中所述事件或状况发生的情况以及所述事件或状况不发生的情况。
术语“被取代的”是指特定原子上的任意一个或多个氢原子被取代基取代，可以包括重氢和氢的变体，只要特定原子的价态是正常的并且取代后的化合物是稳定的。当取代基为氧(即＝O)时，意味着两个氢原子被取代。氧取代不会发生在芳香基上。术语“任选被取代的”是指可以被取代，也可以不被取代，除非另有规定，取代基的种类和数目在化学上可以实现的基础上可以是任意的。
当任何变量(例如R)在化合物的组成或结构中出现一次以上时，其在每一种情况下的定义都是独立的。因此，例如，如果一个基团被0-2个R所取代，则所述基团可以任选地至多被两个R所取代，并且每种情况下的R都有独立的选项。此外，取代基和/或其变体的组合只有在这样的组合会产生稳定的化合物的情况下才是被允许的。
当一个连接基团的数量为0时，比如-(CRR) 0-，表示该连接基团为单键。
当其中一个变量选自单键时，表示其连接的两个基团直接相连，比如A-L-Z中L代表单键时表示该结构实际上是A-Z。
当一个取代基为空缺时，表示该取代基是不存在的，比如A-X中X为空缺时表示该结构实际上是A。当所列举的取代基中没有指明其通过哪一个原子连接到被取代的基团上时，这种取代基可以通过其任何原子相键合，例如，吡啶基作为取代基可以通过吡啶环上任意一个碳原子连接到被取代的基团上。当所列举的连接基团没有指明其连接方向，其连接方向是任意的，例如，
Figure PCTCN2019092997-appb-000039
中连接基团L为-M-W-，此时-M-W-既可以按与从左往右的读取顺序相同的方向连接环A和环B构成
Figure PCTCN2019092997-appb-000040
也可以按照与从左往右的读取顺序相反的方向连接环A和环B构成
Figure PCTCN2019092997-appb-000041
所述连接 基团、取代基和/或其变体的组合只有在这样的组合会产生稳定的化合物的情况下才是被允许的。
除非另有规定，术语“C 1-6烷基”用于表示直链或支链的由1至6个碳原子组成的饱和碳氢基团。所述C 1-6烷基包括C 1-5、C 1-4、C 1-3、C 1-2、C 2-6、C 2-4、C 6和C 5烷基等；其可以是一价(如甲基)、二价(如亚甲基)或者多价(如次甲基)。C 1-6烷基的实例包括但不限于甲基(Me)、乙基(Et)、丙基(包括n-丙基和异丙基)、丁基(包括n-丁基，异丁基，s-丁基和t-丁基)、戊基(包括n-戊基，异戊基和新戊基)、己基等。
除非另有规定，术语“C 1-3烷基”用于表示直链或支链的由1至3个碳原子组成的饱和碳氢基团。所述C 1-3烷基包括C 1-2和C 2-3烷基等；其可以是一价(如甲基)、二价(如亚甲基)或者多价(如次甲基)。C 1-3烷基的实例包括但不限于甲基(Me)、乙基(Et)、丙基(包括n-丙基和异丙基)等。
除非另有规定，术语“C 1-6烷氧基”表示通过一个氧原子连接到分子的其余部分的那些包含1至6个碳原子的烷基基团。所述C 1-6烷氧基包括C 1-4、C 1-3、C 1-2、C 2-6、C 2-4、C 6、C 5、C 4和C 3烷氧基等。C 1-6烷氧基的实例包括但不限于甲氧基、乙氧基、丙氧基(包括正丙氧基和异丙氧基)、丁氧基(包括n-丁氧基、异丁氧基、s-丁氧基和t-丁氧基)、戊氧基(包括n-戊氧基、异戊氧基和新戊氧基)、己氧基等。
除非另有规定，术语“C 1-3烷氧基”表示通过一个氧原子连接到分子的其余部分的那些包含1至3个碳原子的烷基基团。所述C 1-3烷氧基包括C 1-2、C 2-3、C 3和C 2烷氧基等。C 1-3烷氧基的实例包括但不限于甲氧基、乙氧基、丙氧基(包括正丙氧基和异丙氧基)等。
除非另有规定，“C 3-6环烷基”表示由3至6个碳原子组成的饱和环状碳氢基团，其为单环和双环体系，所述C 3-6环烷基包括C 3-5、C 4-5和C 5-6环烷基等；其可以是一价、二价或者多价。C 3-6环烷基的实例包括，但不限于，环丙基、环丁基、环戊基、环己基等。
除非另有规定，“C 4-6环烯基”表示包含至少一个碳-碳双键的由4至6个碳原子组成的部分不饱和的环状碳氢基团，其包括单环和双环体系，其中双环体系包括螺环、并环和桥环，此体系的任意环都是非芳香性的。所述C 4-6环烯基包括C 4-5或C 5-6环烯基等；其可以是一价、二价或者多价。C 4-6环烯基的实例包括但不限于，环丁烯基、环戊烯基、环戊二烯基、环己烯基、环己二烯基等。
除非另有规定，本发明术语“C 6-12芳环”和“C 6-12芳基”可以互换使用，术语“C 6-12芳环”或“C 6-12芳基”表示由6至12个碳原子组成的具有共轭π电子体系的环状碳氢基团，它可以是单环、稠合双环或稠合三环体系，其中各个环均为芳香性的。其可以是一价、二价或者多价，C 6-12芳基包括C 6-10、C 6-9、C 6-8、C 12、C 10和C 6芳基等。C 6-12芳基的实例包括但不限于苯基、萘基(包括1-萘基和2-萘基等)。
除非另有规定，C n-n+m或C n-C n+m包括n至n+m个碳的任何一种具体情况，例如C 1-12包括C 1、C 2、C 3、C 4、C 5、C 6、C 7、C 8、C 9、C 10、C 11、和C 12，也包括n至n+m中的任何一个范围，例如C 1-12包括C 1-3、C 1-6、C 1-9、C 3-6、C 3-9、C 3-12、C 6-9、C 6-12、和C 9-12等；同理，n元至n+m元表示环上原子数为n至n+m个，例如3-12元环包括3元环、4元环、5元环、6元环、7元环、8元环、9元环、10元环、11元环、和12元环，也包括n至n+m中的任何一个范围，例如3-12元环包括3-6元环、3-9元环、5-6元环、5-7元环、 6-7元环、6-8元环、和6-10元环等。
术语“离去基团”是指可以被另一种官能团或原子通过取代反应(例如亲和取代反应)所取代的官能团或原子。例如，代表性的离去基团包括三氟甲磺酸酯；氯、溴、碘；磺酸酯基，如甲磺酸酯、甲苯磺酸酯、对溴苯磺酸酯、对甲苯磺酸酯等；酰氧基，如乙酰氧基、三氟乙酰氧基等等。
术语“保护基”包括但不限于“氨基保护基”、“羟基保护基”或“巯基保护基”。术语“氨基保护基”是指适合用于阻止氨基氮位上副反应的保护基团。代表性的氨基保护基包括但不限于：甲酰基；酰基，例如链烷酰基(如乙酰基、三氯乙酰基或三氟乙酰基)；烷氧基羰基，如叔丁氧基羰基(Boc)；芳基甲氧羰基，如苄氧羰基(Cbz)和9-芴甲氧羰基(Fmoc)；芳基甲基，如苄基(Bn)、三苯甲基(Tr)、1,1-二-(4'-甲氧基苯基)甲基；甲硅烷基，如三甲基甲硅烷基(TMS)和叔丁基二甲基甲硅烷基(TBS)等等。术语“羟基保护基”是指适合用于阻止羟基副反应的保护基。代表性羟基保护基包括但不限于：烷基，如甲基、乙基和叔丁基；酰基，例如链烷酰基(如乙酰基)；芳基甲基，如苄基(Bn)，对甲氧基苄基(PMB)、9-芴基甲基(Fm)和二苯基甲基(二苯甲基，DPM)；甲硅烷基，如三甲基甲硅烷基(TMS)和叔丁基二甲基甲硅烷基(TBS)等等。
本发明的化合物可以通过本领域技术人员所熟知的多种合成方法来制备，包括下面列举的具体实施方式、其与其他化学合成方法的结合所形成的实施方式以及本领域技术上人员所熟知的等同替换方式，优选的实施方式包括但不限于本发明的实施例。
本发明所使用的溶剂可经市售获得。本发明采用下述缩略词：aq代表水；HATU代表O-(7-氮杂苯并***-1-基)-N,N,N',N'-四甲基脲六氟磷酸盐；EDC代表N-(3-二甲基氨基丙基)-N'-乙基碳二亚胺盐酸盐；m-CPBA代表3-氯过氧苯甲酸；eq代表当量、等量；CDI代表羰基二咪唑；DCM代表二氯甲烷；PE代表石油醚；DIAD代表偶氮二羧酸二异丙酯；DMF代表N,N-二甲基甲酰胺；DMSO代表二甲亚砜；EtOAc代表乙酸乙酯；EtOH代表乙醇；MeOH代表甲醇；CBz代表苄氧羰基，是一种胺保护基团；BOC代表叔丁氧羰基是一种胺保护基团；HOAc代表乙酸；NaCNBH 3代表氰基硼氢化钠；r.t.代表室温；O/N代表过夜；THF代表四氢呋喃；Boc 2O代表二-叔丁基二碳酸酯；TFA代表三氟乙酸；DIPEA代表二异丙基乙基胺；SOCl 2代表氯化亚砜；CS 2代表二硫化碳；TsOH代表对甲苯磺酸；NFSI代表N-氟-N-(苯磺酰基)苯磺酰胺；NCS代表1-氯吡咯烷-2,5-二酮；n-Bu 4NF代表氟化四丁基铵；iPrOH代表2-丙醇；mp代表熔点；EDCI代表1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐。
化合物经手工或者
Figure PCTCN2019092997-appb-000042
软件命名，市售化合物采用供应商目录名称。
技术效果：本发明化合物在酶学水平，对于突变的IDH1R132H和IDH1R132C具有良好的抑制作用，同时对于野生型IDH蛋白并无抑制作用；在细胞水平，本发明化合物对于具有IDH1R132H突变的U87MG脑胶质瘤细胞具有良好的2-HG抑制作用；本发明化合物具有显著的IDH1突变体抑制作用和良好的选择性，同时在脑瘤和脑旁组织中的具有更好的分布比例，可降低对正常脑组织的潜在副作用。
具体实施方式
下面通过实施例对本发明进行详细描述，但并不意味着对本发明任何不利限制。本文已经详细地描述了本发明，其中也公开了其具体实施例方式，对本领域的技术人员而言，在不脱离本发明精神和范围的情况下针对本发明具体实施方式进行各种变化和改进将是显而易见的。
流程A
Figure PCTCN2019092997-appb-000043
其中，基团定义如本发明式(Ⅰ)化合物所述。
实施例1
Figure PCTCN2019092997-appb-000044
实施例1A
Figure PCTCN2019092997-appb-000045
(E)-3-(4-氟-3-硝基苯基)丙烯酸甲酯(2g,8.88mmol)和(R)-1-苯基乙胺(1.18g,9.77mmol,1.26mL)的四氢呋喃(20mL)溶液中加入碳酸钾(2.46g,17.76mmol)，混合溶液在50℃下搅拌16小时。反应液用50mL水稀释，然后用乙酸乙酯(30mL×3)萃取，合并的有机相用无水硫酸钠干燥，过滤，减压浓缩得到一个粗品。15℃下，粗品在石油醚：乙酸乙酯＝10:1(11mL)中搅拌30分钟，过滤，固体减压浓缩得到实施例1A。 1H NMR(400MHz,CDCl 3)δ＝8.65(d,J＝5.4Hz,1H),8.35(d,J＝2.1Hz,1H),7.60-7.44(m,2H),7.42-7.29(m,5H),6.70(d,J＝8.9Hz,1H),6.27(d,J＝15.9Hz,1H),4.76(q,J＝6.5Hz,1H),3.80(s,3H),1.70(d, J＝6.7Hz,3H).
实施例1B
Figure PCTCN2019092997-appb-000046
在氮气保护下，实施例1A(1g,3.06mmol)的甲醇(20mL)溶液中加入氯化镍(1.99g,15.32mmol)。冷却至0℃，缓慢加入硼氢化钠(695.57mg,18.39mmol)。混合溶液在15℃下搅拌1小时。加入100mL饱和氯化铵溶液搅拌15分钟淬灭反应。用乙酸乙酯(80mL×3)萃取，合并的有机相用无水硫酸钠干燥，过滤，减压浓缩得到实施例1B，不纯化，直接用于下一步。
实施例1C
Figure PCTCN2019092997-appb-000047
实施例1B(1.1g,3.69mmol)的四氢呋喃(20mL)溶液中加入4-(三氟甲氧基)苯异硫氰酸酯(888.84mg,4.06mmol,)，40℃下搅拌半小时，加入EDC·HCl(1.41g,7.37mmol)在70℃搅拌16小时。反应液用30mL水稀释，然后用乙酸乙酯(30mL×3)萃取，合并的有机相用无水硫酸钠干燥，过滤，减压浓缩得到粗品。经过柱层析纯化得到实施例1C。 1H NMR(400MHz,CDCl 3)δ＝7.43-7.29(m,6H),7.21-7.17(m,2H),7.09-6.98(m,3H),6.91(br d,J＝7.9Hz,1H),5.80(br s,1H),5.67(q,J＝7.1Hz,1H),3.70-3.48(m,3H),2.98(t,J＝7.9Hz,2H),2.61(t,J＝7.9Hz,2H),1.82(d,J＝7.1Hz,3H).
实施例1
Figure PCTCN2019092997-appb-000048
实施例1C(1.35g,2.79mmol)的四氢呋喃(10mL)和水(10mL)的混合溶液中加入氢氧化锂(334.35mg,13.96mmol)，15℃下搅拌16小时，反应液用1M盐酸调节pH至6。用乙酸乙酯(30mL×3)萃取，合并的有机相用无水硫酸钠干燥，过滤，减压浓缩得到粗品。粗品用5毫升乙酸乙酯稀释，向里面加入20毫升石油醚，白色固体析出，过滤，减压浓缩，再用10毫升甲基叔丁基醚稀释，搅拌十分钟，过滤，固体减压浓缩得到实施例1。 1H NMR(400MHz,METHANOL-d4)δ＝7.57(br d,J＝8.9Hz,2H),7.43-7.21(m,8H),6.90-6.63(m,2H),5.97(br d,J＝6.8Hz,1H),3.02-2.83(m,2H),2.59(br t,J＝7.0Hz,2H),2.03-1.92(m,3H).
实施例2
Figure PCTCN2019092997-appb-000049
实施例2A
Figure PCTCN2019092997-appb-000050
向(E)-3-(4-氟-3-硝基苯基)丙烯酸甲酯(2g,8.88mmol)和(S)-1-苯基乙胺(1.08g,8.88mmol)的四氢呋喃(20mL)溶液中加入碳酸钾(2.46g,17.76mmol)，混合溶液在50℃下搅拌16小时。反应液用50mL水稀释，然后用乙酸乙酯(30mL×3)萃取，合并的有机相用无水硫酸钠干燥，过滤，减压浓缩得到一个粗品。15℃下，粗品在石油醚：乙酸乙酯＝10:1(11mL)中搅拌30分钟，过滤，固体减压浓缩得到实施例2A。 1H NMR(400MHz,CDCl 3)δ＝8.65(br d,J＝5.5Hz,1H),8.35(d,J＝2.1Hz,1H),7.56(d,J＝15.9Hz,1H),7.47(dd,J＝2.0,8.9Hz,1H),7.41-7.29(m,5H),6.70(d,J＝9.0Hz,1H),6.27(d,J＝15.9Hz,1H),4.76(q,J＝6.5Hz,1H),3.80(s,3H),1.70(d,J＝6.7Hz,3H).
实施例2B
Figure PCTCN2019092997-appb-000051
在氮气保护下，向实施例2A(1g,3.06mmol)的甲醇(20mL)溶液中加入氯化镍(1.99g,15.32mmol)。冷却至0℃，缓慢加入硼氢化钠(695.57mg,18.39mmol)，混合溶液在15℃下搅拌1小时。加入100mL饱和氯化铵溶液搅拌15分钟淬灭反应，用乙酸乙酯(80mL×3)萃取，合并的有机相用无水硫酸钠干燥，过滤，减压浓缩得到实施例2B，直接用于下一步。
实施例2C
Figure PCTCN2019092997-appb-000052
向实施例2B(950.00mg,3.18mmol)的四氢呋喃(2mL)溶液中加入4-(三氟甲氧基)苯异硫氰酸酯(767.64mg, 3.50mmol)，40℃下搅拌半小时，加入EDCI(1.22g,6.37mmol)，在70℃搅拌16小时。反应液用30mL水稀释，然后用乙酸乙酯(30mL×3)萃取，合并的有机相用无水硫酸钠干燥，过滤，减压浓缩得到粗品，经过柱层析纯化得到实施例2C。 1H NMR(400MHz,CDCl 3)δ＝7.43-7.27(m,6H),7.23-7.17(m,2H),7.07-6.97(m,3H),6.95-6.86(m,1H),5.82(br s,1H),5.67(q,J＝7.0Hz,1H),3.61(s,3H),2.97(t,J＝7.9Hz,2H),2.61(t,J＝7.9Hz,2H),1.82(d,J＝7.1Hz,3H).
实施例2
Figure PCTCN2019092997-appb-000053
向实施例2C(1.33g,2.75mmol)的四氢呋喃(10mL)和水(10mL)的混合溶液中加入氢氧化锂(329.42mg,13.75mmol)，15℃下搅拌16小时，反应液用1M盐酸调节pH至6，用乙酸乙酯(30mL×3)萃取，合并的有机相用无水硫酸钠干燥，过滤，减压浓缩得到粗品。粗品用5毫升乙酸乙酯稀释，向里面加入20毫升石油醚，白色固体析出，过滤，减压浓缩，再用10毫升甲基叔丁基醚稀释，搅拌十分钟，过滤，固体减压浓缩得到实施例2。 1H NMR(400MHz,METHANOL-d4)δ＝7.56(br d,J＝7.2Hz,2H),7.42-7.22(m,8H),6.86-6.71(m,2H),6.03-5.88(m,1H),2.98-2.87(m,2H),2.63-2.53(m,2H),2.05-1.92(m,3H).
实施例3
Figure PCTCN2019092997-appb-000054
实施例3A
Figure PCTCN2019092997-appb-000055
向(E)-3-(4-氟-3-硝基-苯基)丙-2-烯酸甲酯(800mg，3.55mmol)的四氢呋喃(15mL)溶液中加入碳酸钾(982.04mg,7.11mmol)和(1R)-1-(4-氯苯基)乙胺(552.91mg，3.55mmol)，混合物在45℃搅拌20小时。将反应混合物减压浓缩除去溶剂，残余物用100mL水稀释并用乙酸乙酯300mL(100mL×3)萃取，合并的有机层用200mL(100mL×2)饱和氯化钠水溶液洗涤，无水硫酸钠干燥，过滤并减压浓缩得到残余物，残余物经过柱层析纯化得到实施例3A。 1H NMR(400MHz,CDCl 3)δ＝8.58(br d,J＝5.4Hz,1H),8.34 (d,J＝2.1Hz,1H),7.55(d,J＝16.0Hz,1H),7.47(dd,J＝2.1,9.0Hz,1H),7.36-7.32(m,2H),7.29-7.27(m,2H),6.62(d,J＝9.0Hz,1H),6.27(d,J＝16.0Hz,1H),4.71(quin,J＝6.4Hz,1H),3.79(s,3H),1.66(d,J＝6.7Hz,3H).
实施例3B
Figure PCTCN2019092997-appb-000056
向实施例3A(1.01g，2.80mmol)在甲醇(10mL)和四氢呋喃(6mL)的溶液中加入氯化镍(3.33g，14.00mmol)，接着滴加硼氢化钠(1.38g，36.39mmol)的二甲基甲酰胺(3mL)溶液，控制内部温度不超过10℃，将反应混合物在10℃下搅拌1小时。混合物加入水(80mL)和乙酸乙酯(30mL)并通过硅藻土垫过滤，滤饼用乙酸乙酯(40mL×3)洗涤，滤液用乙酸乙酯150mL萃取，合并的有机相用饱和盐水(100mL×2)洗涤，无水硫酸钠干燥并真空浓缩，得到实施例3B，直接用于下一步。
实施例3C
Figure PCTCN2019092997-appb-000057
向实施例3B(711mg，2.14mmol)的四氢呋喃(8mL)溶液中加入1-异硫氰酸基-4-(三氟甲氧基)苯(515.06mg，2.35mmol，381.52μL)，混合物在45℃搅拌1小时，然后加入EDCI(409.53mg，2.14mmol)并将混合物在70℃搅拌15小时。将反应混合物减压浓缩除去溶剂，残余物用水50mL稀释并用乙酸乙酯100mL(50mL×2)萃取，合并的有机层用100mL(50mL×2)饱和氯化钠水溶液洗涤，用无水硫酸钠干燥，过滤并减压浓缩，得到残余物，通过柱色谱(SiO 2，石油醚/乙酸乙酯＝1/0至10：1)纯化，得到实施例3C，直接用于下一步。
实施例3
Figure PCTCN2019092997-appb-000058
向实施例3C(713mg，1.38mmol)的四氢呋喃(4mL)和水(2mL)溶液中加入氢氧化锂(288.84mg，6.88mmol)，混合物在20℃下搅拌16小时。用稀盐酸(1N)将混合物酸化至pH＝6，用乙酸乙酯200mL(100mL×2)萃取，合并的有机层用200mL(100mL×2)饱和食盐水溶液洗涤，无水硫酸钠干燥、过滤并减压浓缩，得 到残余物。残余物通过高效液相色谱法(TFA条件)纯化，得到实施例3D。 1H NMR(400MHz,DMSO-d6)δ＝7.78(br s,2H),7.47(s,6H),7.26(s,1H),6.98-6.76(m,2H),6.14-6.03(m,1H),3.42(br s,2H),2.85(br t,J＝7.3Hz,2H),1.96(br d,J＝6.7Hz,3H)。
实施例4
Figure PCTCN2019092997-appb-000059
实施例4A
Figure PCTCN2019092997-appb-000060
向(E)-3-(4-氟-3-硝基-苯基)丙-2-烯酸甲酯(800mg，3.55mmol)的四氢呋喃(15mL)溶液中加入碳酸钾(982.04mg,7.11mmol)和(1R)-1-(4-氟苯基)乙胺(494.45mg，3.55mmol)，混合物在45℃下搅拌20小时。将反应混合物减压浓缩除去溶剂，残余物用水100mL稀释并用乙酸乙酯300mL(100mL×3)萃取，合并的有机层用200mL(100mL×2)盐水洗涤，用无水硫酸钠干燥、过滤并减压浓缩，得到残余物，残余物通过柱色谱(SiO 2，石油醚/乙酸乙酯＝1/0至5：1)纯化，得到实施例4A。 1H NMR(400MHz,CDCl 3)δ＝8.59(br d,J＝5.1Hz,1H),8.34(d,J＝2.2Hz,1H),7.55(d,J＝15.9Hz,1H),7.48(dd,J＝2.1,8.9Hz,1H),7.34-7.28(m,2H),7.09-7.01(m,2H),6.65(d,J＝8.9Hz,1H),6.27(d,J＝16.0Hz,1H),4.73(quin,J＝6.5Hz,1H),3.79(s,3H),1.66(d,J＝6.7Hz,3H).
实施例4B
Figure PCTCN2019092997-appb-000061
向实施例4A(1.01g，2.93mmol)在甲醇(6mL)和四氢呋喃(6mL)的溶液中加入氯化镍(3.49g，14.67mmol)，然后滴加硼氢化钠(1.44g，38.13mmol)溶于二甲基甲酰胺(3mL)的溶液，控制内部温度不超过10℃，将反应混合物在10℃下搅拌1小时。将混合物倒入水(80mL)和乙酸乙酯(30mL)中并通过硅藻土垫过 滤，滤饼用乙酸乙酯(40mL×3)洗涤，用乙酸乙酯150mL萃取混合物，将合并的有机相用饱和盐水(100mL×2)洗涤，用无水硫酸钠干燥并真空浓缩，得到实施例4B，直接用于下一步。
实施例4C
Figure PCTCN2019092997-appb-000062
向实施例4B(411mg,1.30mmol)的四氢呋喃(6mL)溶液中加入1-异硫氰酰-4-(三氟甲氧基)苯(313.22mg，1.43mmol)，混合物在45℃下搅拌1小时，然后加入EDCI(249.04mg，1.30mmol)并将混合物在70℃下搅拌15小时。将反应混合物减压浓缩除去溶剂，残余物用水50mL稀释并用乙酸乙酯100mL(50mL×2)萃取，合并的有机层用100mL水溶液(50mL×2)洗涤，用无水硫酸钠干燥，过滤并减压浓缩，得到残余物。经过柱层析纯化得到实施例4C，直接用于下一步。
实施例4
Figure PCTCN2019092997-appb-000063
向实施例4C(333mg，664.05μmol)的四氢呋喃(4mL)和水(2mL)溶液中加入氢氧化锂(139.33mg，3.32mmol)，混合物在20℃下搅拌16小时。用稀盐酸(1N，6mL)将混合物酸化至pH＝6，用乙酸乙酯200mL(100mL×2)萃取，将合并的有机层用盐水溶液200mL(100mL×2)洗涤，用无水硫酸钠干燥，过滤并减压浓缩，得到残余物。通过高效液相色谱法(TFA条件)纯化残余物，得到实施例4。 1H NMR(400MHz,DMSO-d6)δ＝7.79(br d,J＝8.4Hz,2H),7.49(br s,4H),7.29-7.21(m,3H),6.95-6.78(m,2H),6.08(br d,J＝7.0Hz,1H),3.44-3.39(m,2H),2.84(br t,J＝7.4Hz,2H),1.96(br d,J＝6.7Hz,3H).
实施例5
Figure PCTCN2019092997-appb-000064
实施例5A
Figure PCTCN2019092997-appb-000065
向(E)-3-(4-氟-3-硝基-苯基)丙烯酸甲酯(500mg，2.22mmol)的四氢呋喃(10mL)溶液中加入碳酸钾(920.67mg，6.66mmol)和(1R)-1-苯基丙-1-胺(330.25mg，2.44mmol，350.58μL)，将混合物在50℃下搅拌16小时。反应混合物用水(20mL)稀释然后用乙酸乙酯(10mL×3)萃取，合并的有机层用盐水(30mL)洗涤，用无水硫酸钠干燥，过滤并减压浓缩得到实施例5A，不纯化直接用于下一步。 1H NMR(400MHz,CDCl 3)δ＝8.67(br d,J＝5.8Hz,1H),8.24(d,J＝2.1Hz,1H),7.46(d,J＝15.9Hz,1H),7.36(dd,J＝2.1,9.0Hz,1H),7.32-7.19(m,6H),6.60(d,J＝9.0Hz,1H),6.16(d,J＝15.9Hz,1H),4.41(q,J＝6.5Hz,1H),3.70(s,3H),1.95-1.85(m,2H),0.96(t,J＝7.4Hz,3H)
实施例5B
Figure PCTCN2019092997-appb-000066
向实施例5A(400mg，1.18mmol)的四氢呋喃(5mL)溶液中加入六水合二氯化镍(1.12g，4.70mmol)，随后逐滴加入硼氢化钠(88.92mg，2.35mmol)的二甲基甲酰胺(1mL)溶液，内部温度不得超过10℃，将反应混合物在10℃下搅拌2小时，然后在0℃下分批补加硼氢化钠(177.84mg，4.70mmol)并在15℃下搅拌2小时。反应混合物用水(20mL)稀释，然后过滤，滤液用乙酸乙酯(20mL×4)萃取，将合并的有机层用盐水(40mL×1)洗涤，用无水硫酸钠干燥，过滤并减压浓缩得到实施例5B，不进一步纯化，直接用于下一步。
实施例5C
Figure PCTCN2019092997-appb-000067
向实施例5B(350mg，1.12mmol)的四氢呋喃(5mL)溶液中加入4-(三氟甲氧基)苯基硫杂异氰酸酯(270.12mg，1.23mmol)，将混合物在25℃下搅拌1小时，然后向该混合物中加入EDCI(429.54mg，2.24mmol)并在70℃下反应2小时。将反应混合物减压浓缩除去四氢呋喃，将残余物用水(10mL)稀释并用乙酸乙酯(10mL×3)萃取，将合并的有机层用HCl(1M，5mL)和盐水(20mL)洗涤，用无水硫酸钠干燥，过滤 并减压浓缩得到实施例5C，不进一步纯化，直接用于下一步。
实施例5
Figure PCTCN2019092997-appb-000068
向实施例5C(500mg，1.01mmol)和水(5mL)中的溶液中加入一水合氢氧化锂(126.52mg，3.02mmol)，将混合物在20℃下搅拌16小时。用HCl(1M水溶液)将混合物的pH调节至6-7，用乙酸乙酯(10mL×4)萃取混合物，将合并的有机层用盐水(20m×1)洗涤，用无水硫酸钠干燥，过滤并减压浓缩，得到残余物，通过高效液相色谱分离(TFA条件)纯化，得到实施例5。 1H NMR(400MHz,METHANOL-d4)δ＝7.67-7.60(m,2H),7.56-7.43(m,6H),7.42-7.36(m,1H),7.32(s,1H),7.08(d,J＝1.0Hz,2H),5.84(dd,J＝5.5,10.1Hz,1H),2.98(t,J＝7.5Hz,2H),2.76-2.65(m,1H),2.65-2.54(m,3H),1.06(t,J＝7.3Hz,3H).
实施例6
Figure PCTCN2019092997-appb-000069
实施例6A
Figure PCTCN2019092997-appb-000070
向(E)-3-(4-氟-3-硝基-苯基)丙-2-烯酸甲酯(800mg，3.55mmol)的四氢呋喃(10mL)溶液中加入(1R)-四氢萘-1-胺(523.04mg，3.55mmol)和碳酸钾(982.04mg，7.11mmol)，将混合物在50℃搅拌16小时。反应混合物减压浓缩除去溶剂，残余物用水100mL稀释并用乙酸乙酯200mL(100mL×2)萃取，合并的有机层用200mL(100mL×2)盐水溶液洗涤，无水硫酸钠干燥、过滤并减压浓缩，得到实施例6A，不纯化，直接用于下一步。
实施例6B
Figure PCTCN2019092997-appb-000071
向实施例6A(1.31g，3.72mmol)的甲醇(10mL)溶液中加入氯化镍(4.42g，18.59mmol)，随后逐滴加入硼氢化钠(1.97g，52.05mmol)溶于二甲基甲酰胺(3mL)的溶液，控制内部温度不超过10℃，将反应混合物在10℃下搅拌16小时，混合物倒入水(100mL)，乙酸乙酯(40mL)中并通过硅藻土垫过滤，滤饼用乙酸乙酯(60mL×3)洗涤，用乙酸乙酯150mL萃取混合物，合并的有机相用饱和盐水(100mL×2)洗涤，无水硫酸钠干燥并减压浓缩，得到实施例6B，不纯化，直接用于下一步。
实施例6C
Figure PCTCN2019092997-appb-000072
向实施例6B(1.09g，2.99mmol)的四氢呋喃(15mL)溶液中加入异硫氰酰-4-(三氟甲氧基)苯(720.97mg，3.29mmol)，将混合物在50℃搅拌1小时，然后加入EDCI(573.25mg，2.99mmol)并将混合物在70℃下搅拌15小时。将反应混合物减压浓缩除去溶剂，残余物用水100mL稀释并用乙酸乙酯200mL(100mL×2)萃取，合并的有机层用200mL(100mL×2)盐水溶液洗涤，用无水硫酸钠干燥，过滤并减压浓缩，得到残余物，残余物通过柱色谱(SiO 2，石油醚/乙酸乙酯＝1/0至12：1)纯化，得到实施例6C。
实施例6
Figure PCTCN2019092997-appb-000073
向实施例6C(1.36g，2.64mmol)的四氢呋喃(10mL)和水(4mL)溶液中加入氢氧化锂(554.44mg，13.21mmol)，混合物在25℃下搅拌16小时。用稀盐酸(1N，4ml)将混合物酸化至pH＝6，并用乙酸乙酯200mL(100mL×2)萃取，将合并的有机层用盐水溶液200mL(100mL×2)洗涤，Na 2SO 4干燥，过滤并减压浓缩，得到残余物，将残余物溶于EA(10mL)并在25℃搅拌30min，然后过滤混合物并用乙酸乙酯(2×10mL)洗涤，得到
实施例6。 1H NMR(400MHz,METHANOL-d 4)δ＝7.60(br d,J＝8.6Hz,2H),7.33-7.15(m,5H),7.04(br t,J＝7.0Hz,1H),6.83(br d,J＝7.6Hz,1H),6.74(br d,J＝7.9Hz,1H),6.41(br d,J＝8.1Hz,1H),5.88(br t,J＝8.1 Hz,1H),3.15-3.01(m,1H),3.00-2.85(m,3H),2.57(br t,J＝7.4Hz,2H),2.30(br s,2H),2.13(br s,1H),2.01(br d,J＝16.1Hz,1H).
实施例7
Figure PCTCN2019092997-appb-000074
实施例7A
Figure PCTCN2019092997-appb-000075
(E)-3-(4-氟-3-硝基苯基)丙烯酸甲酯(0.5g,2.22mmol)和(R)-1-(3-氯苯基)乙胺(380.12mg,2.44mmol)的四氢呋喃(10mL)溶液中加入碳酸钾(613.78mg,4.44mmol)，混合溶液在50℃下搅拌12小时。反应液用30mL水稀释，然后用乙酸乙酯(30mL×3)萃取，合并的有机相用无水硫酸钠干燥，过滤，减压浓缩得到一个粗品。粗品经过柱层析纯化得到黄色油状物实施例7A。 1H NMR(400MHz,CDCl 3)δ＝8.49(br d,J＝5.5Hz,1H),8.26(d,J＝2.1Hz,1H),7.47(d,J＝15.9Hz,1H),7.40(dd,J＝2.0,9.0Hz,1H),7.24(s,1H),7.21-7.16(m,2H),7.16-7.12(m,1H),6.55(d,J＝9.0Hz,1H),6.19(d,J＝15.9Hz,1H),4.62(quin,J＝6.5Hz,1H),3.71(s,3H),1.59(d,J＝6.7Hz,3H).
实施例7B
Figure PCTCN2019092997-appb-000076
在氮气保护下，向实施例7A(0.79g,2.19mmol)的甲醇(10mL)溶液中加入氯化镍(1.42g,10.95mmol)。冷却至0℃，缓慢加入硼氢化钠(828.40mg,21.90mmol)。混合溶液在15℃下搅拌0.5小时。加入50mL饱和氯化铵溶液搅拌15分钟淬灭反应。用乙酸乙酯(50mL×3)萃取，合并的有机相用无水硫酸钠干燥，过滤，减压浓缩得到黄色油状物实施例7B，不进一步纯化，直接用于下一步。
实施例7C
Figure PCTCN2019092997-appb-000077
向实施例7B(0.615g,1.85mmol)的四氢呋喃(10mL)溶液中加入4-(三氟甲氧基)苯异硫氰酸酯(486.02mg,2.22mmol,360.01μL)，40℃下搅拌半小时，加入EDC·HCl(708.46mg,3.70mmol)在70℃搅拌5小时。反应液用30mL水稀释，然后用乙酸乙酯(30mL×3)萃取，合并的有机相用无水硫酸钠干燥，过滤，减压浓缩得到粗品。经过柱层析纯化得到黄色固体实施例7C。
实施例7
Figure PCTCN2019092997-appb-000078
向实施例7C(0.58g,1.12mmol)的四氢呋喃(5mL)和水(5mL)的混合溶液中加入氢氧化锂(234.96mg,5.60mmol)，20℃下搅拌16小时，反应液用1M盐酸调节pH至6，然后用30mL水稀释，乙酸乙酯(30mL×3)萃取，合并的有机相用无水硫酸钠干燥，过滤，减压浓缩得到粗品。粗品经过高效液相色谱法纯化得到实施例7。 1H NMR(400MHz,DMSO-d6)δ＝9.27(s,1H),7.93(d,J＝9.0Hz,2H),7.44-7.32(m,5H),7.28-7.21(m,2H),6.79-6.68(m,2H),6.07(q,J＝6.9Hz,1H),2.82(br t,J＝7.5Hz,2H),2.53(br s,2H),1.90(d,J＝7.0Hz,3H).
实施例8
Figure PCTCN2019092997-appb-000079
实施例8A
Figure PCTCN2019092997-appb-000080
(E)-3-(4-氟-3-硝基-苯基)丙-2-烯酸甲酯(500mg，2.22mmol)的THF(10mL)溶液中加入K 2CO 3 (920.67mg，6.66mmol)和(1R)-茚满-1-胺(325.33mg，2.44mmol，312.81μL)。将混合物在50℃搅拌下16小时。将反应混合物用水(20mL)稀释并用乙酸乙酯(20mL×3)萃取。将合并的有机层用盐水(20mL×2)洗涤，用硫酸钠干燥，过滤并减压浓缩，得到实施例8A。 1H NMR(400MHz,CDCl 3)δ＝8.46(br d,J＝7.0Hz,1H),8.29(d,J＝2.1Hz,1H),7.60(dd,J＝2.1,9.0Hz,1H),7.54(d,J＝15.9Hz,1H),7.31-7.19(m,4H),7.18-7.11(m,1H),7.05(d,J＝9.0Hz,1H),6.26(d,J＝15.9Hz,1H),5.15(q,J＝7.1Hz,1H),3.73(s,3H),3.08-2.99(m,1H),2.96-2.86(m,1H),2.70-2.60(m,1H),2.02-1.96(m,1H).
实施例8B
Figure PCTCN2019092997-appb-000081
实施例8A(720mg，2.13mmol)的MeOH(20mL)和DMF(5mL)溶液中分批加入NiCl 2·6H 2O(2.02g，8.51mmol)和NaBH 4(563.54mg，14.90mmol)。搅拌混合物在0℃下1小时。通过加入水(50mL)淬灭反应混合物，然后用乙酸乙酯(50mL)稀释。过滤混合物并用乙酸乙酯(30mL×3)萃取。将合并的有机层用盐水(100mL×1)洗涤，用硫酸钠干燥，过滤并减压浓缩，得到棕色油状物实施例8B。将残余物不经进一步纯化用于下一步。
实施例8C
Figure PCTCN2019092997-appb-000082
实施例8B(800mg，2.58mmol)的THF(10mL)溶液中加入4-(三氟甲氧基)苯异硫氰酸酯(677.91mg，3.09mmol，502.16μL)。将混合物在30℃搅拌1h。然后加入EDCI(988.19mg，5.15mmol)混合物在70℃下搅拌2小时。反应混合物用水(30mL)稀释并用乙酸乙酯(20mL×3)萃取。将合并的有机层用盐水(30mL×1)洗涤，用硫酸钠干燥，过滤并减压浓缩，得到残余物。通过柱层析纯化得到棕色油状物实施例8C。 1H NMR(400MHz,CDCl 3)δ＝7.52-7.42(m,3H),7.37-7.29(m,2H),7.28-7.18(m,3H),7.11(br d,J＝8.7Hz,2H),7.03-6.93(m,1H),6.06(t,J＝8.3Hz,1H),3.70(s,3H),3.30-3.20(m,1H),3.16-3.09(m,1H),3.06(t,J＝7.8Hz,2H),2.82-2.73(m,1H),2.70(t,J＝7.9Hz,2H),2.34(qd,J＝8.8,13.4Hz,1H).
实施例8
Figure PCTCN2019092997-appb-000083
向实施例8C(450mg，908.19umol)的THF(2mL)和H 2O(2mL)溶液中加入LiOH.H 2O(114.33mg，2.72mmol)。将混合物在20℃搅拌16小时。用HCl水溶液(1M)将混合物的pH调节至7，然后用乙酸乙酯(10mL×3)萃取。将合并的有机层用盐水(20mL)洗涤，用Na 2SO 4干燥，过滤并减压浓缩通过高效液相色谱法纯化得到实施例8。 1H NMR(400MHz,METHANOL-d 4)δ＝7.73-7.59(m,2H),7.56-7.47(m,3H),7.46-7.40(m,1H),7.32-7.20(m,3H),6.96(d,J＝8.3Hz,1H),6.41-6.22(m,2H),3.40-3.34(m,1H),3.20(td,J＝8.5,16.6Hz,1H),2.99-2.93(m,2H),2.92-2.84(m,1H),2.62-2.55(m,2H),2.55-2.46(m,1H).
实施例9
Figure PCTCN2019092997-appb-000084
实施例9A
Figure PCTCN2019092997-appb-000085
向(E)-3-(4-氟-3-硝基苯基)丙烯酸甲酯(0.5g,2.22mmol)和二苯基甲胺(447.60mg,2.44mmol,422.26μL)的四氢呋喃(10mL)溶液中加入碳酸钾(613.78mg,4.44mmol)，混合溶液在50℃下搅拌12小时。再加入二苯基甲胺(81.38mg,444.10umol,76.77μL)，溶液在55℃下搅拌12小时。反应液用30mL水稀释，然后用乙酸乙酯(30mL×3)萃取，合并的有机相用无水硫酸钠干燥，过滤，减压浓缩得到一个粗品。粗品经过柱层析纯化得到黄色固体实施例9A。 1H NMR(400MHz,CDCl 3)δ＝8.74(br d,J＝5.3Hz,1H),8.27(d,J＝1.9Hz,1H),7.48(d,J＝15.9Hz,1H),7.42(dd,J＝1.8,8.9Hz,1H),7.32-7.20(m,10H),6.69(d,J＝9.0Hz,1H),6.19(d,J＝15.9Hz,1H),5.70(d,J＝5.5Hz,1H),3.71(s,3H).
实施例9B
Figure PCTCN2019092997-appb-000086
在氮气保护下，往实施例9A(0.66g,1.70mmol)的甲醇(10mL)溶液中加入氯化镍(1.10g,8.50mmol)。冷却至0℃，缓慢加入硼氢化钠(642.86mg,16.99mmol)。混合溶液在20℃下搅拌0.5小时。加入50mL饱和氯化铵溶液搅拌15分钟淬灭反应。用乙酸乙酯(50mL×3)萃取，合并的有机相用无水硫酸钠干燥，过滤，减压浓缩得到黄色油状物实施例9B,不纯化直接用于下一步。
实施例9C
Figure PCTCN2019092997-appb-000087
向实施例9B(0.41g,1.14mmol)的四氢呋喃(10mL)溶液中加入4-(三氟甲氧基)苯异硫氰酸酯(278mg,1.27mmol,205.93μL)，40℃下搅拌1小时，加入EDC·HCl(436.11mg,2.27mmol)在70℃搅拌12小时。反应液用30mL水稀释，然后用乙酸乙酯(30mL×3)萃取，合并的有机相用无水硫酸钠干燥，过滤，减压浓缩得到粗品。经过柱层析纯化得到黄色固体实施例9C。
实施例9
Figure PCTCN2019092997-appb-000088
实施例9C(0.46g,843.18umol)的四氢呋喃(5mL)和水(5mL)的混合溶液中加入一水合氢氧化锂(176.92mg,4.22mmol)，20℃下搅拌12小时，反应液用1M盐酸调节pH至6，乙酸乙酯(20mL×3)萃取，合并的有 机相用无水硫酸钠干燥，过滤，减压浓缩得到粗品。粗品用10mL石油醚：乙酸乙酯＝10:1稀释，搅拌30分钟，过滤减压浓缩得到实施例9。 1H NMR(400MHz,DMSO-d6)δ＝12.06(br s,1H),9.33(br s,1H),7.90(br d,J＝8.2Hz,2H),7.46-7.35(m,7H),7.32(br d,J＝8.7Hz,2H),7.26(br s,1H),7.20(br d,J＝7.1Hz,4H),6.64(br d,J＝7.8Hz,1H),6.28(br d,J＝8.2Hz,1H),2.81(br t,J＝7.5Hz,2H),2.53(br s,2H).
实施例10
Figure PCTCN2019092997-appb-000089
实施例10A
Figure PCTCN2019092997-appb-000090
向(E)-3-(4-氟-3-硝基-苯基)丙-2-烯酸甲酯(750mg，3.33mmol)的四氢呋喃(10mL)溶液中加入碳酸钾(920.67mg，6.66mmol)和(1R)-1-(2-甲氧基苯基)乙胺(503.52mg，3.33mmol)，将混合物在50℃搅拌16小时。将反应混合物减压浓缩除去溶剂，残余物用水100mL稀释并用乙酸乙酯200mL(100mL×2)萃取，合并的有机层用200mL(100mL×2)盐水溶液洗涤，用无水硫酸钠干燥，过滤并减压浓缩，得到残余物，残余物通过柱色谱(SiO 2，石油醚/乙酸乙酯＝1/0至15：1)纯化，得到实施例10A。
实施例10B
Figure PCTCN2019092997-appb-000091
向实施例10A(1.19g，3.34mmol)在甲醇(10mL)的溶液中加入氯化镍(3.97g，16.70mmol)，随后逐滴加入硼氢化钠(1.39g，36.73mmol)的二甲基甲酰胺(5mL)溶液，控制内部温度不超过10℃，反应混合物在10℃下搅拌16小时。将混合物倒入水(100mL)，乙酸乙酯(40mL)中并通过硅藻土垫过滤，滤饼 用乙酸乙酯(60mL×3)洗涤并用乙酸乙酯150mL萃取滤液，将合并的有机相用饱和盐水(100mL×2)洗涤，用无水硫酸钠干燥并真空浓缩，得到实施例10B。
实施例10C
Figure PCTCN2019092997-appb-000092
向实施例10B(1.11g，3.35mmol)的四氢呋喃(15mL)溶液中加入1-异硫氰酰-4-(三氟甲氧基)苯(734.27mg，3.35mmol，543.90μL)，将混合物在50℃搅拌1小时，然后加入EDCI(642.11mg，3.35mmol)并将混合物在70℃下搅拌15小时。将反应混合物减压浓缩除去溶剂，残余物用水100mL稀释并用乙酸乙酯200mL(100mL×2)萃取，合并的有机层用饱和食盐水溶液200mL(100mL×2)洗涤，经无水硫酸钠干燥，过滤并减压浓缩，得到残余物，通过柱色谱法(SiO2，石油醚/乙酸乙酯＝1/0至6：1)纯化残余物，得到实施例10C。
实施例10
Figure PCTCN2019092997-appb-000093
实施例10C(1.32g，2.49mmol)的四氢呋喃(6mL)和水(3mL)溶液中加入一水合氢氧化锂(523.12mg，12.47mmol)，混合物在25℃下搅拌16小时。用稀盐酸(1N，4ml)将混合物酸化至pH＝6，并用乙酸乙酯200mL(100mL×2)萃取，合并的有机层用饱和食盐水溶液200mL(100mL×2)洗涤，用无水硫酸钠干燥，过滤并减压浓缩，得到的残余物溶于乙酸乙酯(4mL)和石油醚(8mL)的混合溶液并在25℃搅拌60分钟，然后过滤混合物并用乙酸乙酯(1mL)和石油醚(2mL)的混合溶液洗涤滤饼，得到实施例10。 1H NMR(400MHz,CDCl 3)δ＝7.60-7.55(m,2H),7.37-7.32(m,1H),7.28-7.22(m,3H),7.09-7.03(m,3H),6.98(dd,J＝1.5,8.3Hz,1H),6.86(d,J＝8.3Hz,1H),5.78(q,J＝7.1Hz,1H),3.70(s,3H),3.13-2.98(m,2H),2.75-2.61(m,2H),1.88(d,J＝7.1Hz,3H).
实施例11
Figure PCTCN2019092997-appb-000094
实施例11A
Figure PCTCN2019092997-appb-000095
(E)-3-(4-氟-3-硝基-苯基)丙-2-烯酸甲酯(220mg，977.03umol)的四氢呋喃(10mL)溶液中加入碳酸钾(675.15mg,2.931mmol)和(1R)-2,2-二甲基-1-苯基-丙-1-胺盐酸盐(195.13mg，977.03umol)。将混合物在60℃搅拌48小时。将反应混合物减压浓缩除去溶剂，残余物用水100mL稀释并用乙酸乙酯200mL(100mL×2)萃取，合并的有机层用饱和食盐水溶液200mL(100mL×2)洗涤，用无水硫酸钠干燥，过滤并减压浓缩，得到残余物，柱色谱(SiO 2，石油醚/乙酸乙酯＝1/0至12：1)纯化残余物，得到实施例11A。
实施例11B
Figure PCTCN2019092997-appb-000096
向实施例11A(420mg，1.14mmol)在甲醇(6mL)的溶液中加入氯化镍(1.35g，5.70mmol)，随后逐滴添加硼氢化钠((474.42mg,12.54mmol)溶于二甲基甲酰胺(3mL)的溶液，控制内部温度不超过10℃，将反应混合物在10℃下搅拌2小时。将混合物倒入水(80mL)，乙酸乙酯(20mL)中并通过硅藻土垫过滤，滤饼用乙酸乙酯(50mL×3)洗涤，乙酸乙酯100mL萃取混合物，合并的有机相用饱和盐水(80mL×2) 洗涤，用无水硫酸钠干燥并真空浓缩，得到实施例11B，不纯化，直接用于下一步。
实施例11C
Figure PCTCN2019092997-appb-000097
向实施例11B(270mg，793.05umol)的四氢呋喃(5mL)溶液中加入1-异硫氰酸基-4-(三氟甲氧基)苯(173.82mg，793.05μmol，128.76μL)，将混合物在50℃搅拌1小时，然后加入EDCI(167.23mg，872.35μmol)并将混合物在70℃下搅拌15小时。将反应混合物减压浓缩除去溶剂，残余物用水100mL稀释并用乙酸乙酯200mL(100mL×2)萃取，合并的有机层用饱和食盐水溶液200mL(100mL×2)洗涤，无水硫酸钠干燥，过滤并减压浓缩，得到残余物，通过柱色谱法(SiO 2，石油醚/乙酸乙酯＝1/0至10：1)纯化残余物，得到实施例11C。
实施例11
Figure PCTCN2019092997-appb-000098
向实施例11C(373mg,695.52umol)的四氢呋喃(3mL)和水(1mL)溶液中加入氢氧化锂(145.93mg，3.48mmol)，混合物在25℃下搅拌6小时。用稀盐酸(1N，3ml)将混合物酸化至pH＝6，过滤，滤饼用乙酸乙酯20mL洗涤得到残余物。将滤饼溶解于甲醇(10mL)和二氯甲烷(10mL)中，将混合物在80℃搅拌1小时，然后过滤，滤饼即为产物。得到实施例11。 1H NMR(400MHz,DMSO-d6)δ＝9.17(s,1H),7.96(br d,J＝9.0Hz,2H),7.62(br d,J＝7.6Hz,2H),7.41-7.33(m,4H),7.31-7.25(m,1H),7.18(s,1H),6.76(d,J＝8.3Hz,1H),6.63(dd,J＝1.4,8.4Hz,1H),5.86(s,1H),2.78(br t,J＝7.6Hz,2H),2.47-2.52(m,2H),1.22(s,9H).
实施例12
Figure PCTCN2019092997-appb-000099
实施例12A
Figure PCTCN2019092997-appb-000100
(E)-3-(4-氟-3-硝基-苯基)丙-2-烯酸甲酯(0.26g，1.15mmol)溶于乙腈(10mL)中，加入碳酸钾(558.55mg，3.45mmol)和(R)-环丙基(苯基)甲胺盐酸盐(233.30mg，1.27mmol)，在80℃下搅拌2小时。将反应混合物用100mL水稀释并用乙酸乙酯100mL(50mL×2)萃取，将合并的有机层用50mL盐水(50mL×1)洗涤，经硫酸钠干燥，过滤并减压浓缩，通过柱色谱法纯化得到黄油状物实施例12A。 1H NMR(400MHz,CDCl 3)δ＝0.34-0.56(m,2H),0.60-0.80(m,2H),1.30-1.43(m,1H),3.78(s,3H),4.04(dd,J＝7.95,5.38Hz,1H),6.23(d,J＝15.89Hz,1H),6.56(d,J＝8.93Hz,1H),6.52-6.62(m,1H),7.27-7.42(m,6H),7.53(d,J＝15.89Hz,1H),8.32(d,J＝2.08Hz,1H),8.88(br d,J＝5.01Hz,1H).
实施例12B
Figure PCTCN2019092997-appb-000101
向实施例12A(388mg，1.10mmol)和六水合氯化镍(1.31g，5.51mmol)中加入MeOH(6mL)和THF(6mL)，在5℃分批加入硼氢化钠(416.54mg，11.01mmol)，5℃下搅拌0.5小时。加入100mL水将反应混合物淬灭，然后过滤，滤液用乙酸乙酯100mL(50mL×2)萃取，将合并的有机层用50mL盐水(50mL×1)洗涤，经硫酸钠干燥，过滤并减压浓缩得到实施例12B。
实施例12C
Figure PCTCN2019092997-appb-000102
实施例12B(280mg，863.09umol)的THF(15mL)溶液中，加入异硫氰酰-4-(三氟甲氧基)苯(227.01mg，1.04mmol，168.16μL)。加完后，混合物在40℃下搅拌1小时，然后加入EDCI(330.91mg，1.73mmol)，70℃下搅拌1小时。反应混合液减压浓缩除去THF，用80mL水稀释并用乙酸乙酯100mL(50mL×2)萃取，合并的有机层用50mL盐水(50mL×1)洗涤，经硫酸钠干燥，过滤并减压浓缩，通过柱色谱纯化，得到无色油状物实施例12C。 1H NMR(400MHz,CDCl 3)δ＝0.47-0.70(m,3H),0.95-1.07(m,1H),1.74-1.83(m,1H),2.70(t,J＝7.89Hz,2H),3.06(t,J＝7.95Hz,2H),3.69(s,3H),4.84(d,J＝9.54Hz,1H),6.97(dd,J＝8.19,1.34Hz,1H),7.05-7.16(m,3H),7.28-7.33(m,2H),7.40-7.54(m,6H).
实施例12
Figure PCTCN2019092997-appb-000103
实施例12C(0.29g，569.16umol)中加入THF(3mL)，MeOH(3mL)和H 2O(3mL)中的溶液中加入一水合氢氧化锂(119.41mg，2.85mmol)，20℃下搅拌16小时。用1N HCl溶液将反应混合物缓慢调节至p H＝4，并用乙酸乙酯(40mL×2)萃取，将合并的有机层用50mL盐水洗涤，经硫酸钠干燥，过滤并减压浓缩，用MeOH(10mL)打浆，过滤，真空下干燥，得到实施例12。 1H NMR(400MHz,CDCl 3)δ＝4.38(br s,1H),4.79-4.97(m,1H),6.51-6.62(m,2H),7.25-7.27(m,1H),7.27-7.29(m,1H),7.38-7.51(m,5H).
实施例13
Figure PCTCN2019092997-appb-000104
实施例13A
Figure PCTCN2019092997-appb-000105
3,3-二甲基茚-1-酮(3g，18.73mmol)溶于甲苯(40mL)中，再加入四异丙氧化钛(10.64g，37.46mmol，11.05mL)和2-甲基丙烷-2-亚磺酰胺(2.72g，22.48mmol)，60℃搅拌24小时，再补加入2-甲基丙烷-2-亚磺酰胺(2.72g，22.48mmol)和四异丙氧基钛(5.32g，18.73mmol，5.53mL)，在110℃下搅拌16小时。加入水200mL将反应混合物淬灭，然后过滤，滤液用乙酸乙酯160ml(80mL×2)萃取，合并的有机层用80mL盐水(80mL×1)洗涤，经硫酸钠干燥，过滤并减压浓缩，通过柱色谱法纯化得到褐色油状物的化合物实施例13A。 1H NMR(400MHz,CDCl 3)δ＝1.29-1.43(m,15H)2.98(d,J＝19.07Hz,1H)3.34(d,J＝19.20Hz,1H)7.29-7.42(m,2H)7.48-7.58(m,1H)7.76(d,J＝7.70Hz,1H).
实施例13B
Figure PCTCN2019092997-appb-000106
实施例13A(1.4g，5.32mmol)溶于THF(20mL)和水(574.67mg，31.89mmol，574.67μL)中，加入硼氢化钠(1.01g，26.58mmol)，在25℃下搅拌4小时。加入100mL水将反应混合物淬灭，然后用乙酸乙酯100mL(50mL×2)萃取。将合并的有机层用50mL饱和食盐水溶液洗涤，经硫酸钠干燥，过滤并减压浓缩，通过柱色谱法纯化得到白色固体的化合物实施例13B。 1H NMR(400MHz,CDCl 3)δ＝1.21-1.28(m,12H)1.38(s,3H)1.88(dd,J＝12.84,7.46Hz,1H)2.37(dd,J＝12.84,7.21Hz,1H)3.49(br d,J＝6.60Hz,1H)4.88-4.99(m,1H)7.14-7.21(m,1H)7.23-7.29(m,2H)7.51-7.60(m,1H).
实施例13C
(1R)-3,3-二甲基茚-1-胺
Figure PCTCN2019092997-appb-000107
实施例13B(810mg，3.05mmol)的MeOH(8mL)溶液中，加入HCl/二氧六环(4M，3mL)，20℃搅拌0.5小时，用甲基叔丁基醚(15mL)稀释并在25℃下搅拌30分钟，过滤，真空干燥，得到作为白色固体实施例13C。 1H NMR(400MHz,METHANOL-d4)δ＝1.15-1.30(m,3H)1.40-1.50(m,3H)1.93(dd,J＝13.02,8.13Hz,1H)2.53(dd,J＝12.96,7.70Hz,1H)3.31(dt,J＝3.30,1.65Hz,1H)7.21-7.59(m,4H).
实施例13D
Figure PCTCN2019092997-appb-000108
(E)-3-(4-氟-3-硝基-苯基)丙-2-烯酸甲酯(400mg，1.78mmol)的THF(12mL)溶液中，加入碳酸钾(982.04mg,7.11mmol)和实施例13C(491.69mg，2.49mmol)，在65℃搅拌16小时，用水100mL稀释并用乙酸乙酯120mL(60mL×2)萃取，合并的有机层用50mL盐水(50mL×1)洗涤，经硫酸钠干燥，过滤并减压浓缩，通过柱色谱法纯化得到黄色油状物实施例13D。 1H NMR(400MHz,CDCl 3)δ＝1.33(s,3H)1.43(s,3H)1.95(dd,J＝12.72,7.34Hz,1H)2.60(dd,J＝12.65,7.15Hz,1H)3.82(s,3H)5.25(q,J＝7.21Hz,1H)6.34(d,J＝15.89Hz,1H)7.14(d,J＝9.05Hz,1H)7.25-7.27(m,1H)7.27-7.29(m,1H)7.30-7.39(m,2H)7.57-7.73(m,2H)8.38(d,J＝2.20Hz,1H)8.57(br d,J＝7.09Hz,1H).
实施例13E
Figure PCTCN2019092997-appb-000109
实施例13D(300mg，818.75μmol)溶于THF(5mL)和MeOH(5mL)溶液中，加入Pd/C(50mg，10％)，用氢气置换3次，在25℃下在H 2(15psi)下搅拌16小时。过滤，减压浓缩滤液得到棕色油状物实施例13E。
实施例13F
Figure PCTCN2019092997-appb-000110
实施例13E(255mg，753.45umol)溶于THF(8mL)中，加入1-异硫氰酰-4-(三氟甲氧基)苯(198.17mg，904.14μmol，146.79μL)，在40℃搅拌1小时，然后加入EDCI(288.87mg，1.51mmol)，70℃下搅拌1小时。反应混合物减压浓缩除去THF，用80mL水稀释并用乙酸乙酯100mL(50mL×2)萃取，将合并的有机层用50mL盐水(50mL×1)洗涤，经硫酸钠干燥，过滤并减压浓缩，通过柱色谱纯化，然后通过手性拆分得到白色固体化合物实施例13F。 1H NMR(400MHz,CDCl 3)δ＝1.28-1.55(m,6H)2.14-2.72(m,4H)3.06(br s,2H)3.69(s,3H)5.50(br s,1H)6.06(br s,1H)6.92-7.60(m,11H).
实施例13
Figure PCTCN2019092997-appb-000111
向实施例13F(180mg，343.81umol)的MeOH(2Ml)溶液中加入一水合氢氧化锂(43.28mg，1.03mmol)，THF(2mL)和H 2O(2mL)，在25℃搅拌1小时，用1N HCl将反应混合物缓慢调节至pH＝4，然后通过过滤收集沉淀并在真空下干燥，得到实施例13。 1H NMR(400MHz,METHANOL-d4)δ＝1.34(s,3H)1.54(s,3H)2.37(dd,J＝12.65,9.48Hz,1H)2.48-2.63(m,3H)2.90(br t,J＝7.58Hz,2H)6.05-6.37(m,2H)6.69(br d,J＝8.07Hz,1H)6.93(br d,J＝7.58Hz,1H)7.14-7.32(m,4H)7.35-7.42(m,2H)7.59(br d,J＝7.58Hz,2H).
实施例14 实施例15
Figure PCTCN2019092997-appb-000112
实施例14A
Figure PCTCN2019092997-appb-000113
在干燥的瓶子中装入1-(三氟甲基)-1,2-苯并碘代-3-酮(3.28g，10.37mmol)和CuBr(123.96mg，864.15umol，26.32μL)。将瓶子抽空并用氮气重复回填三次。然后，将溶于ACN(40mL)中的叠氮基(三甲基)硅烷(2.49g，21.60mmol，2.84mL)和苯乙烯(900mg，8.64mmol)加入上述瓶子中。将反应混合物在40℃下搅拌1.5小时。将反应混合物用水(40mL)稀释并用DCM(20mL×3)萃取。将合并的有机层用盐水(20mL×1)洗涤，经Na2SO4干燥，过滤并减压浓缩，得到残余物。通过柱层析纯化得到无色油状化合物实施例14A. 1H NMR(400MHz,CDCl 3)δ＝7.50-7.36(m,5H),4.81(dd,J＝5.1,8.4Hz,1H),2.73-2.45(m,2H).
实施例14B
Figure PCTCN2019092997-appb-000114
实施例14A(1.1g，5.11mmol)的MeOH(15mL)溶液中加入CuSO 4(81.59mg，511.21umol，78.46μL)和NaBH 4(290.11mg，7.67mmol)。将混合物在0℃搅拌1h，然后在20℃搅拌16h。反应混合物用水(20mL)稀释并用乙酸乙酯(20mL×3)萃取。将合并的有机层用盐水(20mL×2)洗涤，用无水硫酸钠干燥，过滤并减压浓缩，得到棕色油状物实施例14B，不经进一步纯化用于下一步。
实施例14C
Figure PCTCN2019092997-appb-000115
往(E)-3-(4-氟-3-硝基-苯基)丙-2-烯酸甲酯(600mg，2.66mmol)的THF(10mL)溶液中加入K 2CO 3 (1.10g，7.99mmol)和实施例14B(720mg，3.81mmol)。将混合物在50℃搅拌16小时。然后将混合物在70℃搅拌32小时。将反应混合物减压浓缩除去溶剂。将残余物用水(50mL)稀释并用乙酸乙酯(50mL×3)萃取。将合并的有机层用盐水(50mL)洗涤，用Na 2SO 4干燥，过滤并减压浓缩，得到黄色油状粗产物实施例14C不经进一步纯化即用于下一步。
实施例14D
Figure PCTCN2019092997-appb-000116
向实施例14C(1g，2.54mmol)在MeOH(20mL)中的溶液中加入NiCl 2·6H 2O(2.41g，10.14mmol)。然后在0℃分批加入NaBH 4(959.38mg，25.36mmol)，并将混合物在0℃保持1小时。反应混合物用水(50mL)稀释并用乙酸乙酯(50mL×3)萃取。将合并的有机层用盐水(50mL×1)洗涤，用Na 2SO 4干燥，过滤并减压浓缩，得到棕色油状将残余物实施例14D，不经进一步纯化用于下一步。
实施例14E 实施例14F
Figure PCTCN2019092997-appb-000117
向实施例14D(770mg，2.10mmol)的THF(20mL)中加入1-异硫氰酰-4-(三氟甲氧基)苯(552.78mg，2.52mmol，409.47μL)。将混合物在40℃搅拌1h。然后加入EDCI(805.79mg，4.20mmol)并将混合物在70℃下搅拌2小时。将反应混合物用水(50mL)稀释并用乙酸乙酯(30mL×3)萃取。将合并的有机层用盐水(50mL)洗涤，用Na 2SO 4干燥，过滤并减压浓缩，得到残余物。通过柱层析法纯化得到残余物。残余物通过SFC分离(手性柱：Chiralcel OD-3 50×4.6mm ID，3μm；流动相：A：CO 2，B：甲醇(含有0.05％DEA)；梯度：甲醇5％至40％；流速：3mL每分钟；波长：220nm)，得到实施例14E(保留时间RT＝1.546分钟)和实施例14F(保留时间RT＝1.941分钟)。
实施例14 实施例15
Figure PCTCN2019092997-appb-000118
向实施例14E(220mg，398.93μmol)在MeOH(3mL)和H 2O(3mL)中的溶液中加入LiOH.H 2O(50.22mg，1.20mmol)。将混合物在30℃搅拌16h。将混合物在30℃再搅拌3小时。用HCl(1M)溶液将该混合物的pH调节至5-6，析出固体，过滤并干燥得到实施例14。 1H NMR(400MHz,METHANOL-d4)δ＝7.57-7.47(m,2H),7.43(d,J＝4.4Hz,4H),7.38-7.33(m,1H),7.30(s,1H),7.25(d,J＝8.3Hz,2H),6.88(d,J＝0.6Hz,2H),6.30(dd,J＝3.6,10.5Hz,1H),3.61-3.37(m,2H),2.96(t,J＝7.7Hz,2H),2.61(t,J＝7.7Hz,2H).
向实施例14F(300mg，543.99μmol)在MeOH(4mL)和H 2O(4mL)中的溶液中加入LiOH·H 2O(68.48mg，1.63mmol)。将混合物在30℃搅拌16小时。用HCl(1M)溶液将该混合物的pH调节至5-6，析出固体，过滤并干燥得到实施例15。 1H NMR(400MHz,METHANOL-d4)δ＝7.55-7.49(m,2H),7.43(d,J＝4.4Hz,4H),7.38-7.33(m,1H),7.30(s,1H),7.28-7.21(m,2H),6.87(s,2H),6.30(dd,J＝3.5,10.5Hz,1H),3.56-3.41(m,2H),2.96(t,J＝7.6Hz,2H),2.61(t,J＝7.7Hz,2H).
实验例1：IDH1体外酶活性测试
IDH1突变体催化NADPH依赖的α-KG(α-酮戊二酸)还原为2-HG(2-羟基戊二酸)，消耗的NADPH可以用荧光读出。
试剂：
基础反应缓冲液：50mM KH 2PO 4,pH 7.5,10mM MgCl 2,10％甘油,150mM NaCl,0.05％BSA(牛血清白蛋白),2mM b-ME(2-巯基乙醇),0.003％Brij35(氧乙烯月桂醚)
底物和辅助因子：
IDH1wt(野生型):65μM异柠檬酸+50μM NADP
IDH1(R132H):1500μMα-KG+15μM NADPH
IDH1(R132C):500μMα-KG+15μM NADPH
反应过程：
反应板的孔中加入1.33X的酶(对照孔中不加)、缓冲液和NADP或NADPH(对照孔)，待测化合物溶于100％DMSO后加入酶混合物中(Echo550，纳升级别)，简单离心后孵化60分钟，加入4X底物和辅助因子的混合物开始反应，简单离心后摇振，室温下孵化45分钟。制备3X硫辛酰胺脱氢酶和忍天青的混合物，加入至反应液中测试生成或剩余的NADPH量，简单离心后室温下孵化10分钟，使用多功能的酶标仪Envision测 量(Ex/Em＝535/590nm)。
实验结果见表1和表2：
表1 IDH1体外酶(IDH1R132H)活性IC 50测试结果
Figure PCTCN2019092997-appb-000119
Figure PCTCN2019092997-appb-000120
表2 IDH1体外酶(IDH1R132C、WT)活性IC 50测试结果
Figure PCTCN2019092997-appb-000121
Figure PCTCN2019092997-appb-000122
结论：本发明专利化合物在酶学水平，对于突变的IDH1R132H和IDH1R132C具有良好的抑制作用，同时对于野生型IDH蛋白并无抑制作用。
实验例2：IDH1细胞学活性测试
本研究将化合物与IDH1突变体细胞系共同孵育后，通过LC-MS检测细胞培养上清中的2HG含量来判断化合物对IDH1突变体的抑制活性。IDH1会催化生物体内异柠檬酸还原为α-酮戊二酸(α-KG)，而IDH1突变体则会进一步催化α-KG还原为2-羟戊二酸(2HG)。
U87MG-IDH1-R132H细胞株是通过用IDH1-R132H转染U87MG细胞后筛选得到的可以稳定表达IDH1-R132H突变体的稳转细胞株，HT1080细胞株则含有内源性的IDH1-R132C突变体。
实验流程如下：
1)化合物用DMSO作3倍梯度稀释后加入到细胞培养板中，共10个浓度，每个浓度双复孔。阴性对照孔只含DMSO，阳性对照孔含终浓度为5μM的BAY1436032。所有孔的DMSO终浓度为0.5％。
2)将IDH1突变体细胞株以40000个细胞/孔的密度种入已含化合物的细胞培养板中。将细胞与化合物在37℃、5％CO 2培养箱中共孵育3天。
3)3天后，取10μl细胞培养上清，用200μl ddH 2O水稀释21倍至210μl并混匀，从中取出50μl稀释液加入200μl沉淀剂(含0.4μg/ml D-2-羟基戊二酸 13C5的乙腈)。4000rpm离心10分钟后，取100μl上清用LC-MS检测2-HG的含量。
4)同时平行用ATPlite 1Step试剂盒按说明书方法检测化合物对IDH1突变体细胞株细胞活力的影响。
5)用2HG含量数据及时各浓度化合物对IDH1突变体的抑制率百分比(抑制率％)，计算公式为：
抑制率％＝(CPD-ZPE)/(HPE-ZPE)×100％
用细胞活力数据计算化合物对IDH1突变体细胞株的细胞毒性百分比(细胞毒性％)，计算公式为：
细胞毒性％＝(1-CPD/ZPE)×100％
CPD：化合物孔的信号值
ZPE：阴性对照孔信号平均值，用0.5％DMSO代替化合物
HPE：阳性对照孔信号平均值
6)将抑制率％和细胞毒性％用GraphPad Prism软件拟合剂量效应曲线，并得出测试化合物的IC 50值。
实验结果见表3：
表3 IDH1体外细胞(U87MG)活性IC 50测试结果
Figure PCTCN2019092997-appb-000123
结论：在细胞水平，本发明专利化合物对于具有IDH1R132H突变的U87MG脑胶质瘤细胞具有良好的2-HG抑制作用。
实验例3小鼠体内药代动力学评价
实验目的：
检测本发明化合物在小鼠体内的药代动力学参数
实验方案：
1)实验药品：实施例6；
2)实验动物：8只7-10周龄的雄性CD-1小鼠，分为2组，每组4只；
3)药物配制：尾静脉注射组，称取适量药物，溶于DMSO：20％羟丙基倍他环糊精(HPbCD)＝10：90的混合溶剂中，配置成0.5mg/mL的溶液；灌胃给药组，称取适量药物，溶于DMSO:聚氧乙烯蓖麻油EL(Cremophor EL):5％磺丁基环糊精(Captisol)＝5:10:85，配置成混悬液。
实验操作：
第1组动物通过尾静脉单次注射给予剂量为1mg/kg、浓度为0.5mg/mL的药物，第2组动物通过灌胃给予剂量为20mg/kg、浓度为2mg/mL的化合物。动物于给药后0.0833(仅尾静脉注射组)、0.25、0.5、1、2、4、6、8和24小时交叉采集血浆样品。使用LC-MS/MS方法测定血浆样品中的药物浓度，得出测试药物的动力学参数见表4：
表4 小鼠体内药代动力学评价参数
Figure PCTCN2019092997-appb-000124
Figure PCTCN2019092997-appb-000125
结论：本发明实施例6具有良好的小鼠体内药代动力学性质。

Claims (16)

  1. 式(Ⅰ)所示化合物、其异构体或其药学上可接受的盐，
    Figure PCTCN2019092997-appb-100001
    其中，
    R 1选自C 1-6烷基、C 3-6环烷基和苯基，所述C 1-6烷基、C 3-6环烷基和苯基任选被1、2或3个R a取代；
    R 2和R 3分别独立地选自H、F、Cl、Br、I、OH、NH 2、CN、COOH、C 1-6烷基和C 1-6烷氧基，所述C 1-6烷基和C 1-6烷氧基任选被1、2或3个R b取代；
    或者，R 1和R 2连接在一起，形成一个任选被1、2或3个R c取代的C 4-6环烯基；
    L选自-CH 2CH 2-和-C 3-6环烷基-CH 2-；
    n选自1、2和3；
    R a、R b和R c分别独立地选自F、Cl、Br、I、OH、NH 2、CN、COOH和Me。
  2. 根据权利要求1所述化合物或其药学上可接受的盐，其中，R 1选自C 1-3烷基、环丙烷基和苯基，所述C 1-3烷基、环丙烷基和苯基任选被1、2或3个R a取代。
  3. 根据权利要求2所述化合物、其异构体或其药学上可接受的盐，其中，R 1选自CH 3、CH 2F、CHF 2、CF 3、CH 2CH 3、CH 2CF 3、CH 2CH 2CH 3、C(CH 3) 3、
    Figure PCTCN2019092997-appb-100002
    CH(CH 3) 2和
    Figure PCTCN2019092997-appb-100003
  4. 根据权利要求1～3任意一项所述化合物、其异构体或其药学上可接受的盐，其中，R 2和R 3分别独立地选自H、F、Cl、Br、I、OH、NH 2、CN、COOH、C 1-3烷基和C 1-3烷氧基，所述C 1-3烷基和C 1-3烷氧基任选被1、2或3个R b取代。
  5. 根据权利要求4所述化合物、其异构体或其药学上可接受的盐，其中，R 2和R 3分别独立地选自H、F、Cl、Br、I、OH、NH 2、CN、COOH、CH 3和CH 3O，所述CH 3和CH 3O任选被1、2或3个R b取代。
  6. 根据权利要求5所述化合物、其异构体或其药学上可接受的盐，其中，R 2和R 3分别独立地选自H、F、Cl、Br、I、OH、NH 2、CN、COOH、CH 3、CH 2F、CHF 2、CF 3和OCH 3。
  7. 根据权利要求1所述化合物、其异构体或其药学上可接受的盐，其中，L选自-CH 2CH 2-和
    Figure PCTCN2019092997-appb-100004
  8. 根据权利要求1所述化合物、其异构体或其药学上可接受的盐，其中，结构单元
    Figure PCTCN2019092997-appb-100005
    选自
    Figure PCTCN2019092997-appb-100006
  9. 根据权利要求8所述化合物、其异构体或其药学上可接受的盐，其中，结构单元
    Figure PCTCN2019092997-appb-100007
    选自
    Figure PCTCN2019092997-appb-100008
  10. 根据权利要求1所述化合物、其异构体或其药学上可接受的盐，其中，结构单元
    Figure PCTCN2019092997-appb-100009
    选自
    Figure PCTCN2019092997-appb-100010
    Figure PCTCN2019092997-appb-100011
  11. 根据权利要求10所述化合物、其异构体或其药学上可接受的盐，其中，结构单元
    Figure PCTCN2019092997-appb-100012
    选自
    Figure PCTCN2019092997-appb-100013
    Figure PCTCN2019092997-appb-100014
    Figure PCTCN2019092997-appb-100015
  12. 根据权利要求1～6任意一项所述化合物、其异构体或其药学上可接受的盐，其选自
    Figure PCTCN2019092997-appb-100016
    其中，
    E选自-CH 2-、-CH 2CH 2-、-C(CH 3) 2-和-C(CH 3) 2CH 2-；
    L选自-CH 2CH 2-和
    Figure PCTCN2019092997-appb-100017
    R 1如权利要求2～3任意一项所定义；
    R 2和R 3如权利要求4～6任意一项所定义。
  13. 根据权利要求12所述化合物、其异构体或其药学上可接受的盐，其选自
    Figure PCTCN2019092997-appb-100018
    其中，
    E、L、R 1、R 2和R 3如权利要求12所定义。
  14. 下式所示化合物、其异构体或其药学上可接受的盐，所述化合物选自
    Figure PCTCN2019092997-appb-100019
    Figure PCTCN2019092997-appb-100020
  15. 根据权利要求14所述化合物、其异构体或其药学上可接受的盐，其选自
    Figure PCTCN2019092997-appb-100021
    Figure PCTCN2019092997-appb-100022
    Figure PCTCN2019092997-appb-100023
  16. 根据权利要求1～15任意一项所述的化合物、其异构体或其药学上可接受的盐在制备治疗与IDH1相关疾病的药物中的应用。
PCT/CN2019/092997 2018-06-26 2019-06-26 苯并咪唑衍生物及其作为idh1抑制剂的应用 WO2020001474A1 (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201980039036.1A CN112533903B (zh) 2018-06-26 2019-06-26 苯并咪唑衍生物及其作为idh1抑制剂的应用
CA3104760A CA3104760C (en) 2018-06-26 2019-06-26 Benzimidazole derivatives and use thereof as idh1 inhibitors
EP19827510.9A EP3816158B1 (en) 2018-06-26 2019-06-26 Benzimidazole derivatives and use thereof as idh1 inhibitors
AU2019296173A AU2019296173B2 (en) 2018-06-26 2019-06-26 Benzimidazole derivatives and use thereof as IDH1 inhibitors
KR1020217001715A KR102584855B1 (ko) 2018-06-26 2019-06-26 벤즈이미다졸 유도체 및 idh1 억제제로서의 이의 용도
US17/254,890 US11407717B2 (en) 2018-06-26 2019-06-26 Benzimidazole derivatives and use thereof as IDH1 inhibitors
JP2020573027A JP7258059B2 (ja) 2018-06-26 2019-06-26 ベンズイミダゾール誘導体及びそのｉｄｈ１阻害剤としての応用
EA202190009A EA202190009A1 (ru) 2018-06-26 2019-06-26 Производные бензимидазола и их применение в качестве ингибиторов idh1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810672394 2018-06-26
CN201810672394.3 2018-06-26

Publications (1)

Publication Number Publication Date
WO2020001474A1 true WO2020001474A1 (zh) 2020-01-02

Family

ID=68986184

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/092997 WO2020001474A1 (zh) 2018-06-26 2019-06-26 苯并咪唑衍生物及其作为idh1抑制剂的应用

Country Status (9)

Country Link
US (1) US11407717B2 (zh)
EP (1) EP3816158B1 (zh)
JP (1) JP7258059B2 (zh)
KR (1) KR102584855B1 (zh)
CN (1) CN112533903B (zh)
AU (1) AU2019296173B2 (zh)
CA (1) CA3104760C (zh)
EA (1) EA202190009A1 (zh)
WO (1) WO2020001474A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021129587A1 (zh) * 2019-12-23 2021-07-01 昆药集团股份有限公司 一种idh1突变体抑制剂的盐型、晶型及其制备方法

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958506A (zh) * 2011-09-27 2014-07-30 诺华股份有限公司 用作突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物
WO2015121209A1 (en) * 2014-02-11 2015-08-20 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
WO2016171756A1 (en) * 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
WO2017009325A1 (en) * 2015-07-16 2017-01-19 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles as midh1 inhibitors
WO2017012967A1 (en) * 2015-07-21 2017-01-26 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
US20170107194A1 (en) * 2013-07-11 2017-04-20 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2018010637A1 (en) * 2016-07-14 2018-01-18 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
CN107641114A (zh) * 2016-07-21 2018-01-30 南京圣和药业股份有限公司 作为异柠檬酸脱氢酶抑制剂的化合物及其应用
CN107848985A (zh) * 2015-07-27 2018-03-27 拜耳制药股份公司 制备取代的3‑(2‑苯胺基‑1‑环己基‑1h‑苯并咪唑‑5‑基)丙酸衍生物的方法
CN107849059A (zh) * 2015-07-27 2018-03-27 伊莱利利公司 7‑苯基乙基氨基‑4h‑嘧啶并[4,5‑d][1,3]噁嗪‑2‑酮化合物及其作为突变体idh1抑制剂的用途
WO2018071404A1 (en) * 2016-10-11 2018-04-19 Isocure Biosciences Inc. Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007514794A (ja) * 2003-12-19 2007-06-07 メルク　エンド　カムパニー　インコーポレーテッド 環式グアニジン、そのような化合物を含む組成、及び使用方法
WO2008153701A1 (en) 2007-05-24 2008-12-18 Schering Corporation Compounds for inhibiting ksp kinesin activity
BRPI0814874A2 (pt) * 2007-07-31 2019-09-24 Schering Corp combinação de agente antimitótico e inibidor da aurora quinase como tratamento anticâncer.
WO2009059214A1 (en) * 2007-11-02 2009-05-07 The Regents Of The University Of California Abeta-binding small molecules
JP2011520969A (ja) 2008-05-19 2011-07-21 シェーリング コーポレイション 二環式ヘテロ環誘導体およびｇｐｒ１１９モジュレーターとしてのその使用
WO2012174312A2 (en) 2011-06-15 2012-12-20 Glaxosmithkline Llc Benzimidazole derivatives as antiviral agents
US9957235B2 (en) 2014-02-11 2018-05-01 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as mIDH1 inhibitors
CA2971872C (en) 2014-12-22 2023-10-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Mutant idh1 inhibitors useful for treating cancer
TWI817929B (zh) 2016-07-29 2023-10-11 美商瑞佩特治療公司 趨化介素受體調節劑及其用途

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958506A (zh) * 2011-09-27 2014-07-30 诺华股份有限公司 用作突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物
US20170107194A1 (en) * 2013-07-11 2017-04-20 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015121209A1 (en) * 2014-02-11 2015-08-20 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
WO2016171756A1 (en) * 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
WO2017009325A1 (en) * 2015-07-16 2017-01-19 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles as midh1 inhibitors
WO2017012967A1 (en) * 2015-07-21 2017-01-26 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
CN107848985A (zh) * 2015-07-27 2018-03-27 拜耳制药股份公司 制备取代的3‑(2‑苯胺基‑1‑环己基‑1h‑苯并咪唑‑5‑基)丙酸衍生物的方法
CN107849059A (zh) * 2015-07-27 2018-03-27 伊莱利利公司 7‑苯基乙基氨基‑4h‑嘧啶并[4,5‑d][1,3]噁嗪‑2‑酮化合物及其作为突变体idh1抑制剂的用途
WO2018010637A1 (en) * 2016-07-14 2018-01-18 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
CN107641114A (zh) * 2016-07-21 2018-01-30 南京圣和药业股份有限公司 作为异柠檬酸脱氢酶抑制剂的化合物及其应用
WO2018071404A1 (en) * 2016-10-11 2018-04-19 Isocure Biosciences Inc. Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACTA NEUROPATHOL, vol. 133, 2017, pages 629 - 644
DANG L, NATURE, vol. 462, no. 7274, 10 December 2009 (2009-12-10), pages 739 - 44
HARTMANN C, ACTA NEUROPATHOL, no. 4, October 2009 (2009-10-01), pages 469 - 74

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021129587A1 (zh) * 2019-12-23 2021-07-01 昆药集团股份有限公司 一种idh1突变体抑制剂的盐型、晶型及其制备方法
AU2020412071B2 (en) * 2019-12-23 2023-08-10 Kpc Pharmaceuticals, Inc Salt form and crystal form of mutant IDH1 inhibitor and preparation method therefor

Also Published As

Publication number Publication date
EA202190009A1 (ru) 2021-03-25
CA3104760A1 (en) 2020-01-02
KR20210022078A (ko) 2021-03-02
US20210206728A1 (en) 2021-07-08
KR102584855B1 (ko) 2023-10-05
EP3816158C0 (en) 2023-10-25
JP2021529200A (ja) 2021-10-28
CN112533903B (zh) 2022-08-16
EP3816158B1 (en) 2023-10-25
CA3104760C (en) 2023-09-26
US11407717B2 (en) 2022-08-09
EP3816158A4 (en) 2022-01-26
CN112533903A (zh) 2021-03-19
JP7258059B2 (ja) 2023-04-14
EP3816158A1 (en) 2021-05-05
AU2019296173A1 (en) 2021-02-04
AU2019296173B2 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
LV11174B (en) (-)-££4- (1,4,5,6- tetrahydro- 4- methyl- 6- oxo- 3- pyridazinyl ) phenyl-|- hydrazono| propanedinitrile
WO2020035065A1 (zh) 作为ret抑制剂的吡唑衍生物
WO2006080323A1 (ja) ヘテロ６員環化合物及びその用途
TWI640510B (zh) Ｃｘｃｒ７受體調節劑
WO2021058024A1 (zh) Lsd1抑制剂
WO2022237797A1 (zh) 烷基羧酸化合物及其应用
WO2020001474A1 (zh) 苯并咪唑衍生物及其作为idh1抑制剂的应用
TW202227093A (zh) 一種硼酸酯衍生物及其用途
CN114008046B (zh) 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物
CN114096245B (zh) 作为ccr2/ccr5拮抗剂的杂环烷基类化合物
CN110582495B (zh) 作为tnf活性的调节剂的稠合五环咪唑衍生物
CN111566091A (zh) 用于治疗疼痛和疼痛相关病症的新的烷氧基氨基衍生物
CN115403594A (zh) 含氮三并环类化合物及其应用
WO2022057836A1 (zh) 苯并脲环衍生物及其制备方法和应用
WO2020156568A1 (zh) 作为pd-l1免疫调节剂的氟乙烯基苯甲酰胺基化合物
TW202227458A (zh) 含有稠合三環的化合物及其醫藥用途
JP2023523830A (ja) ピリミジン系三環式化合物及びその使用
WO2021233349A1 (zh) 吡啶类衍生物及其应用
JP5876419B2 (ja) アリールベンジルアミン化合物
EA040879B1 (ru) Производные бензимидазола и их применение в качестве ингибиторов idh1
WO2019007284A1 (zh) 咔唑酰胺类衍生物或其盐及其制备方法和用途
WO2022228365A1 (zh) 六元杂芳并脲环的衍生物及其应用
WO2022143779A1 (zh) 含烯基类化合物及其应用
WO2022268119A1 (zh) 亚磺酰亚胺类化合物及其应用
WO2023232135A1 (zh) Pde4b抑制剂及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19827510

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3104760

Country of ref document: CA

Ref document number: 2020573027

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20217001715

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019827510

Country of ref document: EP

Effective date: 20210126

ENP Entry into the national phase

Ref document number: 2019296173

Country of ref document: AU

Date of ref document: 20190626

Kind code of ref document: A